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Abstract
Diseases such as periodontal disease, chronic inflammatory bowel disease and autoimmune
disease are reported to be associated with changes in the bacteria populations in specific locations
of the body, particularly the gastrointestinal tract and the oral cavity. Because oral and
gastrointestinal microbiomes do not typically invade tissues in the host with chronic inflammatory
disease, considerable work has instead focused on virulence factors produced by these organisms
and their role in triggering innate immune responses that may promote chronic inflammatory
diseases. Toll-like receptors (TLRs) are innate immune receptors that recognize specific structural
moieties shared among microbes of different classes. My work has concentrated on developing
mass spectrometry (MS)-based technologies to study the structure-function characteristics of a
subclass of complex lipids called lipopeptides that engage TLR2. A significant structure-activity
relationship is controlling TLR2 binding for lipopeptides and the resulting activation of immune
responses. Separation power of chiral liquid chromatography (cLC) and a diastereomeric mixture
of isotopically labeled internal standards were utilized to develop a novel method of cLC stable

isotope dilution multiple reaction monitoring MS (cLC-SID-MRM MS) to simultaneously
determine structure and amount of stereoisomers of lipopeptides. In the second part of the study,
similar MS-based approaches were applied to study the relationship between enzymatic hydrolysis
of these lipopeptides and human disease. This work identified a novel function for phospholipase
A2 (PLA2) enzymes. The combination of

18

O-labeling and MS was used to investigate the

hydrolysis reaction. Furthermore, cLC-MRM MS was utilized to investigate stereoselectivity of
PLA2 enzymes for the hydrolysis of a specific class of lipopeptides. Overall, this work provides
novel methods for structure elucidation and quantitation of bacteria-derived lipopeptides as well
as their expression in specific human inflammatory diseases.
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Chapter 1

1 Introduction
1.1 Human microbiome in health and disease
Human body consists of many interacting systems that functionally connect organs, tissues
and cellular communities. However, more than 90% of the cells in and on the human body are
microbial cells. As a result, the human microbiome must be considered in human
biology.(Pflughoeft, Versalovic 2012) The US National Institutes of Health (NIH) launched the
Human Microbiome Project as one its Roadmap Initiatives, which cost US$140 million for its
completion.(Turnbaugh, Ley et al. 2007)The main aims of the project were to investigate the
diversity of human microbiome and to evaluate the relationship between human microbiome and
human health and disease.(Blaser, Falkow 2009)
An individual’s health status, diet, hygiene and genotype can change the microbiome
diversity.(Pflughoeft, Versalovic 2012) Also, it was suggested that the microbiome can be helpful
for the human body by preventing the invasion of pathogens,(Medzhitov 2001) shaping our
immune response(Medzhitov 2001) and providing nutrients for our body.(Kau, Ahern et al. 2011)
On the other hand, they can cause acute or chronic diseases.(Pflughoeft, Versalovic 2012, Wade
2013, Bennett, Dolin et al. 2014) Therefore considerable work has focused on understanding how
changes in the human microbiome can be correlated with changes in human health.(Pflughoeft,
Versalovic 2012)
Bacteria are the most studied group of human microbiome. Human-associated bacteria are
categorized into four phyla, the “big-four”: Actinobacteria, Firmicutes, Proteobacteria and
1

Bacteroidetes.(Bik 2009) It is important to understand how the diversity and complexity of human
microbiome changes with age. We are born without oral, intestinal and genitourinary bacteria.
However, bacterial communities increase their complexity to an adult-like complexity by the end
of first year of life.(Pflughoeft, Versalovic 2012) Localized disease such as periodontal disease
and also systemic disorders such as autoimmune disease are shown to be related to changes in the
bacterial populations found in specific locations in the body.(Tanzer, Livingston et al. 2001,
Pflughoeft, Versalovic 2012, Darveau 2010, Scannapieco 2013, Curtis, Zenobia et al. 2011,
Honda, Littman 2016) Infectious bacterial pathogens can invade and initiate an immune response,
which can lead to disease or can be controlled by our immune system. In addition, microbial
pathogens or commensal bacteria can produce virulence factors that interact with the host without
direct invasion, formation of invading colonies and/or without elicting a host immune
system.(Medzhitov 2001)
1.2 Toll-like receptors
Understanding how the body detects the presence of infectious agents without destroying
self-tissues has been an area of intensive investigation that has led to the discovery of toll-like
receptors (TLRs).(Chtarbanova, Imler 2011, Medzhitov 2001) TLRs are a class of pattern
recognition receptors (PRRs) that can detect constitutive and conserved products of microbes,
including lipopolysaccharide, lipoproteins, flagella, RNA and DNA.(Medzhitov 2001) Other
pattern recognition receptors are known to exist in host immune cells including NOD receptors
and numerous others. The microbial products recognized by PRRs are called pathogen-associated
molecular patterns (PAMPs). Innate immunity can differentiate self from non-self when PAMPs
are detected by TLRs. The following are characteristic features of the innate immune system.
PAMPs are unique to microorganisms and are not expressed by host cells. Some of the metabolic
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pathways that produce PAMPs are essential for the microorganism survival and are conserved
across many types of organisms. As a result, various species, genera, and phyla of bacteria produce
similar products with conserved structural components such as the lipid A in lipopolysaccharide
(LPS) produced by all Gram negative bacteria. In contrast, the O-antigen portion of LPS is variable
and unique among all species of Gram negative organisms.(Medzhitov 2001) Molecules such as
LPS are called molecular signatures of the microbes. In 2011, the Nobel Prize in physiology for
medicine was awarded to Bruce A. Beutler and Jules A. Hoffmann for their work on TLRs as the
key components in recognition of microbial pathogens by the immune system and to Ralph M.
Steinman for his discovery of the dendritic cell engagement of TLRs and how this bridges between
innate and adaptive immunity.(Volchenkov, Sprater et al. 2012)
1.2.1 TLRs structure
TLRs are type I transmembrane receptors. They are characterized by an extracellular
leucine-rich repeat (LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain.(Rock,
Hardiman et al. 1998) The LRR domain is responsible for molecular recognition. Similarly, a
diverse set of proteins that play a role in TLR molecular recognition and signal transduction
possess LRR domains.(Kobe, Deisenhofer 1995) The intracellular TIR domain, on the other hand,
is the conserved signaling domain of the TLRs, which shares homology with signaling domain of
IL-1R family members.(O'Neill, Bowie 2007) The LRR domain is separated from TIR domain by
the transmembrane (TM) domain, which spans the cell membrane (Figure 1).(Medzhitov 2001)

3

Figure 1. Structure of TLRs. TLRs have three domains: LRR domain that is the recognition domain, the
transmembrane domain spanning the cell membrane and the TIR domain that is responsible for intracellular
signal transduction.

1.3 Lipopeptides
Lipopeptides are amphiphilic molecules which contain a peptide head-group attached to
one or more lipid chains. The peptide head-group of lipopeptides can be cyclic or linear.(Hamley
2015) Natural lipopeptides are commonly produced by bacteria and can be recognized by toll-like
receptors (TLRs) that are located on the cell surface of immune cells.(Schenk, Belisle et al. 2009)
TLR2 is usually responsible for lipopeptide recognition. When recognizing lipopeptides, TLR2
heterodimerizes with either TLR1 or TLR6 depending on the number of acyl chains within the
lipopeptide structure.(Jin, Kim et al. 2007, Kang, Nan et al. 2009) For example, binding of the triacylated lipopeptide, Pam3CSK4, mediates the heterodimerization of TLR1 and TLR2 but not
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TLR6 (Figure 2.).(Kang, Nan et al. 2009) On the other hand, di-acylated lipopeptides engage TLR6
and TLR2. Due to immunological activity of lipopeptides, there is great interest in using these
molecules in vaccine development and antibiotics.

Figure 2. Heterodimerization of TLR1 and TLR2 upon recognition of Pam3CSK4 lipopeptide.
Adopted from Jin et al 2009.

1.3.1 Lipopeptides in vaccine development and antibiotics
Bacterial or synthetic lipopeptides constitute very potent and nontoxic vaccine adjuvants
and they are replacing more traditional adjuvants such as alum salts as there are concerns regarding
alum toxicity.(Moyle, Toth 2008, Ghaffar, Marasini et al. 2016) More importantly, lipopeptides
can produce widespread immune responses without using adjuvants. As a result, lipopeptides can
offer a new class of self-adjuvant vaccines.(Moyle, Toth 2008, BenMohamed, Wechsler et al.
2002) In fact, lipopeptides as self-adjuvanting lipopeptide vaccine have been tested in human
clinical trials.(Moyle, Toth 2008) Furthermore, lipopeptides can act as a new class of antibiotics
against drug-resistant bacteria.(Laurens, Bruin 2014, Grau-Campistany, Manresa et al. 2016,
5

Deshpande, Hurless et al. 2016, Cochrane, Vederas 2016) In summary, lipopeptides are becoming
a very important class of peptides for pharmaceutical investigations. Therefore the design,
synthesis, and quantitation of these molecules in complex biological matrices is of great
importance.
1.3.2 Lipopeptides in activating TLRs
Significant structure-activity relationships dictate the TLR binding following stimulation
of innate immune responses by lipopeptides.(Buwitt‐Beckmann, Heine et al. 2005, Spohn, BuwittBeckmann et al. 2004, Gisch, Kohler et al. 2013, Seyberth, Voss et al. 2006) More importantly, it
is suggested that the recognition of lipopeptides by TLRs can be stereoselective.(Takeuchi,
Kaufmann et al. 2000, Wu, Li et al. 2010, Muhlradt, Kiess et al. 1998, De Zoysa, Cameron et al.
2015, Chang, Varamini et al. 2015, Konno, Abumi et al. 2015, Yin, Li et al. 2015) As a result,
determination of the absolute configurations of the chiral building blocks of the stereoisomers of
lipopeptides as well as separation and quantitation of stereoisomers of lipopeptides is required in
order to identify new agonists for TLRs, investigate cellular and molecular mechanisms involved
in their immunogenicity, and/or to design and synthesize new antibiotics and self-adjuvanting
vaccines.(BenMohamed, Wechsler et al. 2002, Takeuchi, Kaufmann et al. 2000, De Camp 1993)
1.4 Mass spectrometry-based approaches for structure elucidation and quantitation of
lipopeptides
Mass spectrometry (MS) along with nuclear magnetic resonance (NMR) are the most
frequently utilized technologies to determine the structure of lipopeptides.(Iwasaki, Ohno et al.
2015, Gill, Berrué et al. 2014, Naing, Lee et al. 2015, Ma, Hu et al. 2014a, Gisch, Kohler et al.
2013) Tandem mass spectrometry (MS/MS) analysis of lipopeptides provides structural
information complementary to NMR results needed for structure elucidation of lipopeptides.
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Structure elucidation of lipopeptides generally requires high resolution MS/MS spectra acquired
using high resolution MS platforms such as matrix-assisted laser desorption/ionization-time of
flight (MALDI-TOF), electrospray ionization-Fourier transform ion cyclotron resonance (ESIFTICR) or orbitrap mass analyzers.(Vater, Niu et al. 2015, Mnif, Grau-Campistany et al. 2016,
Ma, Hu 2014, HÖLTZEL, Schmid et al. 2002, Jiang, Gao et al. 2016, Sharma, Mandal et al. 2014,
Ma, Hu et al. 2014b) On the other hand, MS-based approaches for quantitation of lipids and
lipopeptides usually utilize ESI-multiple reaction monitoring (MRM) MS using triple quadrupole
(QqQ) instruments.(Tsai, Sun et al. 2013, Rubio, Moore et al. 2012, Eom, Kang et al. 2016, Qi,
Morena et al. 2015, Li, Hu et al. 2013)
1.4.1 Multiple reaction monitoring for targeted analysis of lipids and lipopeptides
MRM or selected reaction monitoring (SRM) is the gold standard for targeted quantitation
of peptides and proteins.(Lange, Picotti et al. 2008, Picotti, Aebersold 2012) MRM was originally
applied to the measurement of small molecules and metabolites and upon emergence of the field
of lipidomics, MS platforms and data analysis software solutions allow for targeted quantitation
of lipids as well.(Lam, Shui 2013, Peng, Ahrends 2015, Guo, Chen et al. 2012, Zweigenbaum,
Henion 2000) MRM is particularly useful when a set of known analytes are available and a precise,
sensitive and multiplex method can be applied to multiple samples.(Picotti, Aebersold 2012)
MRM utilizes the capability of QqQ mass spectrometer for targeted analysis. The first and
third quadrupoles select a specific predefined m/z value for the lipid precursor and its
corresponding product ions, respectively, and the second quadrupole acts as a collision cell. Each
set of precursor-fragment ions is called a transition. In a MRM experiment, several transitions are
monitored over time and the number of fragment ions reaching the detectors versus time is
recorded (Figure 3).(Lange, Picotti et al. 2008) In order to increase confidence in the specificity
7

of MRM detection, two to four transitions are monitored for each analyte.(Lange, Picotti et al.
2008) MRM also demonstrates excellent sensitivity due to the non-scanning nature of MRM
experiments compared to conventional full scanning methods. The most important advantage of
MRM is the capability of monitoring hundreds of transitions in a single experiment. This is
particularly important in biomarker discovery pipeline where the biomarker candidates need to be
validated with a highly multiplexed method.(Picotti, Aebersold 2012)

Figure 3. Multiple reaction monitoring technique. Precursor ions that are generated in the ion source
enter the first quadrupole. Specific lipid precursor is selected in Q1 and is fragmented in Q2. When two
transitions are monitored, only two predefined fragment ions pass through Q3 alternately and hit the
detector. Intensity of the two transitions is monitored over the course of an MRM experiment.

1.4.2 Stable isotope dilution for accurate quantitation
MS is not intrinsically quantitative and quantitation of lipids and lipopeptides in complex
biological samples requires accurate, sensitive, precise, and reproducible measurements. Several
approaches can be employed for relative or absolute quantitation of lipid and lipopeptide
molecules. Stable isotope dilution (SID) is the method of choice when accurate measurement is
required.(Picotti, Aebersold 2012) LC-SID-MRM MS has shown great promise for targeted
quantitation of lipid and lipopeptide molecules in complex biological matrices.(Verdier, Bentué-
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Ferrer et al. 2011, Tsai, Sun et al. 2013, Levison, Zhang et al. 2013, Cheng, Liu et al. 2010, Jansson,
Karvanen et al. 2009) An isotopically labeled internal standard (IS) provides an almost identical
response factor in MS for the analyte of interest and the same retention time in LC, which are
required for accurate quantitation.(Yang, Han 2011) IS must be added to the samples as early as
possible to correct for experimental and instrumental variabilities. Isotope-labeled IS of known
quantity is added into biological samples and quantification is achieved by comparing ion signals
from isotope-labeled IS and native lipids or lipopeptides in samples with high specificity and
precision.(Keshishian, Addona et al. 2007)
1.4.3 Limitations of mass spectrometry-based approaches for the study of lipid and
lipopeptide stereoisomers
Understanding the mechanisms for biological activation by lipids and lipid-modified
molecules such as lipopeptides have proven to be difficult as lipids and lipopeptides are unique
biological molecules in that they are not typically comprised of smaller subunits as seen with
proteins, nucleic acids, or carbohydrates.(Kyle, Zhang et al. 2016) Moreover, lipid and lipopeptide
stereoisomers result from small variations in their structure, which lead to unique roles in lipid
homeostasis and pathology.(Kyle, Zhang et al. 2016) Therefore, one must be able to differentiate
these stereoisomers in order to investigate the physiological roles of these lipids and
lipopeptides.(Hullin-Matsuda, Luquain-Costaz et al. 2009) On the other hand, conventional MS,
MS/MS or MRM analyses are not capable of differentiating stereoisomers of lipids or lipopeptides.
These isomers produce the same MS/MS spectra. Therefore, additional separation based on
orthogonal molecular properties to those used in conventional MS and LC is needed to address
this analytical challenge.
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1.5

Separation of stereoisomers of lipopeptides

1.5.1 Challenges in separation of stereoisomers
Separation of stereoisomers of lipids and lipopeptides with multiple chiral centers is
challenging. Reversed phase (RP) and normal phase (NP) LC-MS methods are not able to separate
certain stereoisomers.(BenMohamed, Wechsler et al. 2002, Han, Yang et al. 2012). One possibility
is the gas-phase separation based on differential ion mobility of stereoisomers inside mass
spectrometers.(Jónasdóttir, Papan et al. 2015, Shvartsburg, Isaac et al. 2011, Kyle, Zhang et al.
2016) Another approach is to exploit the chiral property of stereoisomers of lipopeptides and
utilize chiral liquid chromatography.(Chen, Yamamoto et al. 2007) Chiral liquid chromatography
(cLC) utilizes chiral stationary phases (CSPs) with excellent chiral recognition abilities to separate
stereoisomers.
1.5.2 Methods for separation of stereoisomers of lipopeptide
Several methods are available to achieve separation of stereoisomers such as enzymatic
kinetic resolution,(Kamal, Azhar et al. 2008, Pellissier 2008) crystallization,(Kinbara 2005, Peng,
He et al. 2012) ion mobility mass spectrometry(Jónasdóttir, Papan et al. 2015) and
chromatographic separation.(Jibuti, Mskhiladze et al. 2012) Ion mobility mass spectrometry or gas
phase separation and chromatographic separation methods are described in details in the next
section as these methods were implemented to separate stereoisomers of lipopeptides.
1.5.2.1 Gas-phase separation: Ion mobility mass spectrometry
Ion mobility (IM) MS is an emerging technology that has been applied to lipidomics
recently.(Paglia, Kliman et al. 2015) Three contemporary IM techniques which have shown great
promise for separation of lipids prior to MS detection include (a) conventional drift time ion
10

mobility in which separation of ions is based on differential drift down a continuous declining
potential field upon introduction into a gas-filled chamber, (b) traveling wave ion mobility
whereby ions are separated in a gas-filled chamber using a dynamic traveling potential hill field,
and (c) asymmetric field ion mobility or differential mobility spectrometry which separates ions
based on their different ion migration orthogonal to the direction of a sweeping gas.(Kliman, May
et al. 2011, Paglia, Kliman et al. 2015) In terms of instrumentation, ion mobility is added as a
feature to mass spectrometers. In other words, it shares an ion source, mass analyzer and detector
within the mass spectrometer. However, contrary to mass spectrometers that function only with
high internal vacuum, ion mobility needs a pressurized chamber typically held between 1 and 760
Torr. Separation of ions in IM is related to ions’ physical size or so called the ion collision cross
section. In an ideal experiment, IM can provide gas-phase separation of ions, which is orthogonal
to LC-MS. Therefore, IM data can be considered as a new dimension in LC-MS analysis.
Commercially IM-MS instruments are available although they are relatively expensive. SelexION
technology or differential mobility spectrometry (DMS) are available in QTRAP 5500 and 6500
series instruments from Sciex, MA3100 system available in Thermo mass spectrometers and
SYNAPT G2-Si and Vion IMS QTOF available in the latest versions of IM MS instruments from
Waters.
The main use for IM in lipid analysis is to provide complementary analysis in MS for major
lipid classes according to their chemical structures in shotgun lipidomics.(Paglia, Kliman et al.
2015, Kliman, May et al. 2011) IM separates ions in the gas phase based on charge, molecular
shape, and size, so when coupled with MS, three major benefits to traditional lipidomic approaches
can be obtained. First, IM-MS is capable of determining the collision cross section (CCS), which
is related to the conformational structure of lipid ions. Therefore, CCS enhances the confidence in
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structure elucidation of lipid isomers. Second, IM-MS makes it possible to combine collisioninduced dissociation (CID) fragmentation with IM separation to improve the specificity of
MS/MS. Third, IM-MS enhances the peak capacity and also signal-to-noise ratio of conventional
analytical approaches.(Paglia, Kliman et al. 2015, Basit, Pontis et al. 2016) IM MS can be also
exploited for separation of stereoisomers.(Dwivedi, Wu et al. 2006, Giles, Wildgoose et al. 2010,
Schneider, Covey et al. 2010, Dong, Shion et al. 2010) Gas phase separation of stereoisomers using
conventional drift time ion mobility requires the presence of chiral modifier in the drift
tube.(Dwivedi, Wu et al. 2006) However, DMS has been utilized to separate stereoisomers of
leukotrienes and protectins without the use of chiral modifier.(Jónasdóttir, Papan et al. 2015)
Although IM MS is a promising approach to separate stereoisomers, the accessibility of these
instruments is limited due to the high cost of purchase and maintenance. Also, analytical merits of
these instruments for quantitation of lipids and lipopeptides in complex biological matrices is yet
to be determined.
1.5.2.2 Chiral liquid chromatography separation of stereoisomers
Direct chiral separation using chiral stationary phases (CSPs) for high-performance liquid
chromatography (HPLC) is recognized as the most reliable tool for separation of stereoisomers,
which will be discussed in detail below.(Aboul-Enein, Ali 2003, Ribeiro, Maia et al. 2014,
Nageswara Rao, Guru Prasad 2015) Although chiral separations can be achieved using chiral
mobile phases for HPLC, the application of chiral mobile phases is limited.(Hare, Gil-Av 1979)
Direct chiral separation using chiral mobile phases has some disadvantage: a) chiral additives are
usually expensive or have to be synthesized, b) the instrument operation can be complicated and
c) downstream sample preparation is required as the chiral additives must be removed after
separation. In addition to HPLC, supercritical fluid chromatography (SFC) has received increasing
12

attention.(Kalíková, Šlechtová et al. 2014) SFC has advantages of high resolution, low organic
solvent consumption and short analysis time.(Abbott, Veenstra et al. 2008, Petersson, Markides
1994) SFC has been used recently for chiral separation of stereoisomers of pharmaceutical and
natural products.(Qiao, An et al. 2014, Miller 2012) Due to its high efficiency, speed and success
rate in chiral separation, SFC surpasses HPLC in some drug development projects.(Abbott,
Veenstra et al. 2008)
The separation mechanism for CSPs is the formation of diastereomeric complexes with
different energies on the CSPs (the three-point interaction model). Hydrogen bonding, π-π
interactions, dipole-dipole interactions, steric hindrance, hydrophobic interactions, and
electrostatic interactions are the main interactions utilized in CSPs in order to separate
stereoisomers.(Ikai, Okamoto 2009) Depending on the type of CSPs used for HPLC separations,
one or more of interactions mentioned above play a role in chiral recognition and separation.
Stereoisomer separation ability of CSP can be quantitatively evaluated using three factors:
retention factor (k), separation factor (R), and resolution factor (Rs), defined as follows:
𝑘1 =

(𝑡1−𝑡0)

𝑘2 =

𝑡2−𝑡0

𝛼=
𝑅𝑠 =

𝑡0

𝑡0
𝑘2
𝑘1
2 ×(𝑡2−𝑡1)
𝑊2+𝑊2

(1)

(2)

(3)

(4)

Where t0, t1 and t2 are retention times for the non-retained compound, first-, and second-eluted
stereoisomers respectively, and k1 and k2 are retention factors. W1 and W2 are peak widths at the
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bases and Rs is the chromatographic resolution. Retention factor k manifests the degree of
interaction between stereoisomers and the CSP and Rs corresponds to the recognition ability of a
CSP and theoretical plate number of a column. The Rs value is related to the energy difference
(∆∆G) in the interactions between the CSP and an individual stereoisomer and the relation is
defined as follows:
(∆∆G) = -RT ln Rs

(5)

A suitable CSP should provide a sufficient ∆∆G so that a successful separation is achieved.
Usually, the baseline separation of stereoisomers corresponds to an R = 1.20, which requires (∆∆G)
= -0.46 kJ/mol.(Ikai, Okamoto 2009)
CSPs for HPLC can be prepared using a wide variety of compounds and polymers. One
type of CSPs that use small molecules: amino acids,(Davankov 2003, Bocian, Skoczylas et al.
2016) cyclodextrins,(Muderawan, Ong et al. 2006, Li, Wei et al. 2016, Xiao, Ng et al. 2012, Hyun
2016) crown ethers,(Hyun 2005, Hyun 2016) π-basic or π-acidic aromatic compounds,(Pirkle,
Finn et al. 1981, Kacprzak, Lindner 2011) macrocyclic glycopeptide,(Ilisz, Berkecz et al. 2006,
Barhate, Wahab et al. 2015, Ilisz, Grecsó et al. 2015) and cinchona alkaloid.(Hoffmann,
Laemmerhofer et al. 2007, Lajkó, Orosz et al. 2016) The other type is polymer-based CSPs that
use either synthetic or natural chiral polymers. Examples of synthetic polymers are
polymethacrylates,(Okamoto, Honda et al. 1981, Dong, Zheng et al. 2015) molecularly imprinted
polymers,(Maier,

Lindner

2007,

Blaschke

1986,

Dong,

Zheng

et

al.

2015)

polyacrylamide,(Blaschke 1986, Ciogli, D'Acquarica et al. 2010) and poly(maleimide).(Gao, Isobe
et al. 2007) Proteins(Millot 2003, Bocian, Skoczylas et al. 2016, Liang, Wang et al. 2014) and
polysaccharides(Ikai, Okamoto 2009, Shen, Ikai et al. 2014) are also natural polymer CSPs. These
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polymers are usually coated on silica gel to enhance their mechanical strength and resolution
efficiency.(Ikai, Okamoto 2009)
1.5.2.2.1 Polysaccharide chiral stationary phases
Polysaccharide CSPs are the most popular CSPs for HPLC.(Chen, Yamamoto et al. 2007,
Chankvetadze 2012) In order to improve chiral recognition of polysaccharides, extensive studies
on the modification of these CSPs started in 1980s.(Chankvetadze 2012, Francotte, Wolf et al.
1985, Koller, Rimböck et al. 1983) Modified cellulose and amylose CSPs have shown particularly
exceptional chiral recognition ability.(Chen, Yamamoto et al. 2007, Ikai, Okamoto 2009) Among
the various polysaccharide derivatives, esters and carbamates have been studied intensively and
shown excellent chiral recognition.(Chankvetadze 2012) For example, cellulose and amylose
phenylcarbamate derivatives coated on silica are commercially available chiral selectors (Figure
4).
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Figure 4. Structures of phenylcarbamate derivatives of polysaccharides. Structure of (a) Cellulose and
(b) amylose carbamate derivatives. (c) R1 and R2 are phenyl groups that are modified with either methyl
or chlorine groups. Thicker lines indicate bonds where phenyl groups are attached to carbamate group of
CSP.

Recognition ability of phenylcarbamate polysaccharide CSPs changes with substituents on
the phenyl group. Cellulose phenylcarbamate (Figure 4a) with electron-withdrawing substituents,
such as halogens, or electron-donating substituents, such as alkyl groups, show better chiral
recognitions compared with the non-substituted cellulose derivatives. These substituents perturb
the electronic property of the carbamate group via inductive effect. Therefore, the interaction mode
between cellulose derivatives and chiral analytes is affected. For example, the acidity of the NH
group of the carbamate group increases when electron-withdrawing substituents are introduced
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and the retention time of acetone increases.(Ikai, Okamoto 2009) This is because the hydrogenbonding interaction between acetone and NH group increases. Chiral recognition of
phenylcarbamate derivatives also depends on the position of substituents on the phenyl
group.(Chankvetadze, Yashima et al. 1994) Phenylcarbamate derivatives with high recognition
ability form lyotropic liquid crystallinity in highly concentrated solution under a polarizing
microscope when they are cast from a solution. However, some positions for substituents do not
form such a liquid crystalline phase, which is believed to be important for efficient chiral
recognition.(Okamoto, Kawashima et al. 1986)
For amylose phenylcarbamates (Figure 4b), similar to cellulose phenylcarbamates,
introduction of electron-donating or electron-withdrawing substituents such as methyl or chlorine
on the phenyl groups improves chiral recognition ability of the corresponding amylose CSPs.(Ikai,
Okamoto 2009) Differences in chiral recognition based on the nature and position of substituents,
however, are observed between cellulose and amylose phenylcarbamates. For example, 5-chloro2-methylphenylcarbamate, ortho position of the substituents, exhibits a relatively higher
recognition ability for amylose phenylcarbamates than cellulose phenylcarbamates.(Chen,
Yamamoto et al. 2007)
1.5.2.2.2 Chiral recognition mechanism of polysaccharide derivatives CSPs
NMR spectroscopy, x-ray and computational methods have been used to elucidate the
mechanism of chiral recognition by polysaccharide CSPs.(Ikai, Okamoto 2009) High-ordered
helical structures of the phenylcarbamates of cellulose and amylose is the primary factor
determining chiral recognition. It is suggested that phenylcarbamates of cellulose and amylose
have the left-handed 3/2 and 4/3 helical conformations, respectively.(Steinmeier, Zugenmaier
1987, Vogt, Zugenmaier 1983) The different substituent effects on their chiral recognition may
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also be partially due to differences in their helical structures. Glucose residues are regularly
arranged along the helical axis, and polar carbamate groups surround a chiral helical groove, which
exists along the main chain of polysaccharide. Polar carbamate groups are residing inside whereas
hydrophobic aromatic groups are extending outside of the polymer chain.(Ikai, Okamoto 2009)
Hydrogen bonding interactions between the racemate and NH or C=O groups of phenylcarbamate
or π–π interactions between phenyl groups of phenylcarbamates and an aromatic group of a
racemate on the chiral groove of CSP may play a role in chiral discrimination.(Chen, Yamamoto
et al. 2007)

1.6 Dissertation objectives
1.6.1 Development of a method of cLC-SID-MRM MS for separating and quantifying
stereoisomers of lipopeptides in biological samples
This investigation presents a novel LC-MS method for separation and quantitation of
stereoisomers

of

lipopeptides.

Synthetic

(3R,S)-(15-methyl-3-((13-

methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine) stereoisomers abbreviated as (R,S)Lipid 654 (Figure 5), an agonist for TLR2, are used as model compounds for the development of
a novel cLC-SID-MRM MRM method. The cLC method and column selection are carried out
using a functional group index based on hundreds of chiral compound screens. Three cellulose and
amylose chiral polysaccharide columns are chosen. A synthetic deuterated form of (R,S)-Lipid
654 named as (R,S)-Lipid 654-D9 is used as IS for quantification of Lipid 654 stereoisomers in
bacterial samples. MRM transitions for Lipid 654 and IS are selected based on their MS/MS
spectra using high resolution mass spectrometers. CE and DP voltages for the transitions are
optimized. (R,S)-Lipid 654 stereoisomers are separated with Lux-4 column, and are quantified
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simultaneously using separated Lipid 654-D9. Calibration curves are generated for both isoforms
of Lipid 654 using serially diluted IS added to bacterial lipid extracts. Total lipid extract of nine
bacteria strains are spiked with a known amount of IS and analyzed using the developed cLC-SIDMRM MS. These results are compared with RP LC-SID-MRM MS analysis of the same samples
in order to validate the results obtained by the cLC-SID-MRM MS method.

Figure 5. Structure of synthetic R- and S-Lipid 654 stereoisomers and their MS/MS spectra. (a)
Both isoforms of Lipid 654 have L-serine, but the other chiral center on the fatty acid moiety (circled in
red) can have R or S configurations. (b) MS/MS spectra for R- and S-Lipid 654 stereoisomers; CE -40 V
was used for both isoforms.

It has been shown that the recognition of lipopeptides by TLRs can be stereoselective.
Therefore, there is a need to develop analytical methods to determine the absolute configurations
of chiral constituents of lipopeptide stereoisomers. Furthermore, separation and accurate, precise
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and sensitive quantification of these stereoisomers can accelerate the identification of new agonists
for TLRs, investigation of cellular and molecular mechanisms involved in immunogenicity, or
design of new antibiotics, vaccine adjuvant or self-adjuvanting vaccines. The method of cLC-SIDMRM MS offers several advantages. Using a racemic mixture of isotopically labeled ISs of Lipid
654 and the separation power of cLC, we simultaneously determined the stereochemistry and
accurately quantified the amount of Lipid 654 stereoisomers in biological matrices. Also, MRM
MS analysis offered multiplexed and sensitive analysis of stereoisomers when coupled with cLCSID. This robust method doesn’t require costly and high maintenance instrumentation of IM-MS.
1.6.2 Investigation of the relationship of human disease with Lipid 654 and Lipid 430
Preliminary data from NP LC-MRM MS analysis of bacteria samples as well as human
serum and tissue samples suggests the presence of another lipopeptide molecule related to Lipid
654. Mass of the new lipopeptide is 430 and thus the new molecule is accordingly named as Lipid
430 (Figure 6). Lipid 430 has a similar structure as Lipid 654, but lacks the ester-linked C15:0 fatty
acid. We aim to compare the level of Lipid 430 and Lipid 654 in bacteria samples as well as in
various biological samples LC-SID-MRM MS.

Figure 6. Structure of Lipid 430. Lipid 430 lacks ester-bound C15:0 fatty acid compared to Lipid 654.
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Previous results also showed that the level of Lipid 430 compared to Lipid 640 varies in
bacteria and tissue samples. We also investigated whether changing relative levels of Lipid 654
and Lipid 430 in tissue samples can be due to metabolic conversion (hydrolysis) of Lipid 654 to
Lipid 430 and whether this hydrolysis is due to increased activity of specific esterase enzymes in
disease tissues. Lastly, racemic Lipid 430 and Lipid 654 are synthesized and cLC-MRM MS is
utilized to evaluate stereoselectivity of PLA2 hydrolysis of Lipid 654.
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Chapter 2

2. Chiral liquid chromatography and a mixture of isotopic diastereomer internal standards
for simultaneous determination of the stereochemistry and quantitation of stereoisomers
of lipopeptides in biological samples

2.1 Introduction

Recent advances in mass spectrometry (MS) platforms and data analysis have guided
researchers towards new breakthroughs in the regulation of cellular metabolism and in a better
understanding of etiology of human disease by using metabolomics and lipidomics
approaches.(DeBerardinis, Thompson 2012, Kolovou, Kolovou et al. 2015) Coupling MS to
chromatographic separation can reduce matrix effects of complex biological samples. Liquid
chromatography-MS (LC-MS) and gas chromatography-MS (GC-MS) are the most applied
chromatography-MS

tools

for

analysis

of

non-volatile

and

volatile

metabolites

respectively.(Cajka, Fiehn 2015, Wolfender, Marti et al. 2015) Lipidomics is an important
subcategory of metabolomics and can be classified into untargeted or shotgun and targeted
approaches.(Xu, Valenzuela et al. 2013, Wang, Wang et al. 2016) Untargeted lipidomics centers
on the analysis of all the detectable lipids in biological samples whereas targeted lipidomics is the
analysis of predefined groups of lipids. Both untargeted and targeted approaches have their own
advantages and limitations.(Cajka, Fiehn 2015) In an untargeted lipidomics analysis more lipid
molecules are monitored or quantified, however, more reliable and accurate measurements are
achieved using targeted approaches. For example, the ideal approach in quantitative lipidomics is
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using isotopically labeled internal standard (IS) of the analyte, which is not practical when
untargeted lipidomics is performed due to the excessive number of analytes to be
monitored.(Cajka, Fiehn 2015) This is because isotopically labeled ISs are expensive or not
available for all the analytes. Also, we deal with unknown lipids as well in untargeted lipidomics.

Lipopeptides can be considered as special subclass of complex lipids or peptides because
they contain a cyclic or linear peptide head-group attached to one or more lipid chains.(Hamley
2015, Schneider, Müller et al. 2014, Patel, Ahmed et al. 2015, Mandal, Barbosa et al. 2013, Deleu,
Crowet et al. 2014) Natural lipopeptides, commonly produced by bacteria, and synthetic
lipopeptides can be recognized by toll-like receptors (TLRs) that are located on the cell surface of
immune cells as well as different cell types of periodontium.(Schenk, Belisle et al. 2009,
Khakpour, Wilhelmsen et al. 2015, Basto, Leitao 2014, Li, Lee et al. 2013, Mahanonda,
Pichyangkul 2007) Bacterial or synthetic lipopeptides constitute very potent vaccine adjuvants
without showing the toxicity of more traditional adjuvants such as alum salts,(Moyle, Toth 2008,
Ghaffar, Marasini et al. 2016, Kelesidis, Falagas 2015, Ortwine, Sutton et al. 2015) More
importantly, lipopeptides can lead to general systemic immune responses without using
adjuvants.(Moyle, Toth 2008, BenMohamed, Wechsler et al. 2002, Basto, Leitao 2014)
Lipopeptides may also act as a new class of antibiotics against drug-resistant bacteria.(Laurens,
Bruin 2014, Baltz 2012, Patel, Ahmed et al. 2015) Hence, lipopeptides are becoming a very
important target for pharmaceutical investigations and accurate quantitation of these molecules in
complex biological matrices is of a great importance.

Furthermore, significant structure-activity relationships dictate TLR binding of synthetic
lipopeptides and subsequent stimulation of innate immune responses.(Buwitt‐Beckmann, Heine
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et al. 2005, Spohn, Buwitt-Beckmann et al. 2004, Gisch, Kohler et al. 2013, Seyberth, Voss et al.
2006) It has been shown that the recognition of lipopeptides by TLRs can be
stereoselective.(Takeuchi, Kaufmann et al. 2000, Wu, Li et al. 2010, Muhlradt, Kiess et al. 1998)
Takeuchi et al. showed that preferentially R-stereoisomer of the mycoplasmal lipopeptide
macrophage-activating lipopeptide-2 (MALP-2) activates immune cells through a TLR2- and
MyD88-dependent pathway.(Takeuchi, Kaufmann et al. 2000) Also, Wu et al. synthesized
analogues of MALP-2 and they showed (R)-diacylthioglycerol analogues are maximally active in
reporter gene assays using human TLR2.(Wu, Li et al. 2010) Their results indicated that the
stereochemistry of the peptide component of the synthetic lipopeptides is not a critical determinant
of the activity. On the other hand, the stereochemistry of lipid moiety of lipopeptides as well as
the acyl chain length of ester bound fatty acids turned to be critical for their activity. A minimum
of eight carbons for the ester-bound fatty acids was found to be essential, with shorter acyl
analogues being inactive. Therefore, developing tools to determine the absolute structure of and
quantity of lipopeptide stereoisomers in biological samples is extremely important. These findings
are therefore relevant to the identification of new agonists for TLRs, to the investigation of the
cellular and molecular mechanisms involved in their immunogenicity, as well as to help design
and synthesize new self-adjuvanting vaccines.(BenMohamed, Wechsler et al. 2002, De Camp
1993, Takeuchi, Kaufmann et al. 2000)

Elucidation of complete structure of lipopeptides requires determination of absolute
configuration of all chiral building blocks; chiral amino acids and if present, 3-hydroxyalkanoic
acid.(Biniarz, Łukaszewicz et al. 2016, Barbaro, Zangrando et al. 2014, Ma, Hu 2014)
Lipopeptides can be hydrolyzed into amino acids and fatty acids. Analysis of amino acids can use
indirect methods including pre-column derivatization coupled with either GC-MS or LC44

MS.(Huang, Hu et al. 2013, Müller, Fonseca et al. 2014) Chiral LC-MS (LC-MS) and enantiopure
standards have been utilized to directly determine the configuration of amino acids(Barbaro,
Zangrando et al. 2014, Horak, Gerhardt et al. 2014, Ianni, Pataj et al. 2014, Tsai, Sun et al. 2013)
as well as stereochemistry of 3-hydroxyfatty acids that are released upon hydrolysis of
lipopeptides.(Gerhardt, Sievers-Engler et al. 2016, Ianni, Pataj et al. 2014) Nuclear magnetic
resonance (NMR) spectrometry and MS/MS analysis using high resolution mass spectrometers are
complementary techniques for comprehensive elucidation of the absolute structure of
lipopeptides.(Gerhardt, Sievers-Engler et al. 2016, Iwasaki, Ohno et al. 2015) While hydrolysis of
lipopeptides into amino acids and lipids could be time-consuming, fast and sensitive methods to
simultaneously determine stereochemistry of lipopeptides and quantify them is absent in the
literature.

Quantitation of stereoisomers of lipopeptides in complex biological samples require
accurate, sensitive, precise, and reproducible measurements. Stable isotope dilution multiple
reaction monitoring (SID-MRM) using a triple quadrupole mass spectrometer is the gold standard
for targeted omics analysis and a promising approach for quantitation of lipids and lipopeptides in
complex biological matrices.(Picotti, Aebersold 2012, Keshishian, Addona et al. 2007, Levison,
Zhang et al. 2013, Gelhaus, Mesaros et al. 2011, Rønning, Madslien et al. 2015, Tsai, Sun et al.
2013, Verdier, Bentué-Ferrer et al. 2011, Cheng, Liu et al. 2010, Jansson, Karvanen et al. 2009)
As mentioned previously, an isotopically labeled IS is a preferred reference for accurate MS
quantitation.(Yang, Han 2011) A known quantity of isotope-labeled IS is added to biological
samples (a process called stable isotope diluation [SID]) and quantification with high specificity,
multiplexing capability, and precision is achieved by comparing MS signals from isotope-labeled
and native lipopeptides.(Keshishian, Addona et al. 2007) However, direct application of SID45

MRM MS of stereoisomers of lipopeptides requires prior knowledge of stereochemistry of the
target molecules and preparation of stereochemically-pure isotopic IS. These analysis challenges
can be overcome by hyphenating appropriate front-end separation with SID-MRM MS.

Separation of stereoisomers of lipopeptides with multiple chiral centers is challenging
when using conventional reversed-phase (RP) and normal phase (NP) LC methods.(Laurens, Bruin
2014, Han, Yang et al. 2012) Instead, separation of chiral isomers utilizing different molecular
properties from those for RP and NP LC are needed. One possibility is the use of gas-phase
separation based on differential ion mobility of stereoisomers.(Shvartsburg, Isaac et al. 2011,
Jónasdóttir, Papan et al. 2015a) Utilizing the separation power of ion mobility mass spectrometry
(IM-MS) requires having access to these platforms that are not available in most laboratories due
to their high cost. Another approach exploits the chiral properties of stereoisomers of lipopeptides
and chiral LC.(Chen, Yamamoto et al. 2007) cLC uses chiral stationary phases (CSPs) and can
achieve excellent separation of stereoisomers.(Chen, Yamamoto et al. 2007) Many CSPs have been
developed based on proteins,(Haginaka 2008, Juvancz, Szejtli 2002) oligosaccharides(Juvancz,
Szejtli 2002) and polysaccharides,(Chen, Yamamoto et al. 2007) and optically-active synthetic
polymers.(Nakano 2001) for chromatographic separation of stereoisomers.

Polysaccharide CSPs are widely used for chiral separation. In particular, phenylcarbamate
derivatives of cellulose and amylose immobilized on silica gel have shown excellent chiral
recognition abilities.(Ikai, Okamoto 2009) High-ordered helical structures of cellulose and
amylose provide a molecular basis for chiral recognition.(Chen, Yamamoto et al. 2007) Depending
on substituents and their positions on the phenyl groups, recognition selectivity of these derivatives
can significantly change. Electron-withdrawing and electron-donating substituents such as
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chlorine and methyl groups, respectively, exhibit different chiral recognition by changing the
electronic property of the carbamate group, which in turn affects the interactions of CSP and
stereoisomers.(Ikai, Okamoto 2009) Combining the separation power of cLC and SID-MRM MS,
enabled us to develop a robust method to accurately quantify stereoisomers of lipopeptides.

Herein, a novel method of chiral LC-SID-MRM MS, coined as cLC-SID-MRM MS, is
presented to simultaneously determine stereochemistry of and quantify the amount of stereoisomers
of

lipopeptides

in

biological

samples.

(3R,3S)-(15-methyl-3-((13-

methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine) lipopeptide stereoisomers abbreviated as
(R,S)-Lipid 654, which belong to a new class of TLR2 ligands,(Clark, Cervantes et al. 2013) were
used as model compounds for method development (Figure 1a). Using in-vitro and in-vivo studies,
Clark et al. showed that Lipid 654 isolated from total lipid extract of P. gingivalis bacteria engages
both human and mouse TLR2. In-vitro experiments showed that Lipid 654 activate TLR2-expressing
HEK cells, and this activation was inhibited by anti-TLR2 neutralizing antibody. Also,
administration of Lipid 654 to wild type (WT) mice resulted in a significant increase of chemokine
CCL2. However, TLR2-deficient (TLR2-/-) mice showed no increase upon intravenous
administration of Lipid 654.(Clark, Cervantes et al. 2013) These findings were followed by an
assessment of Lipid 654 in the human systemic circulation. Farrokhi et al. showed that Lipid 654
routinely gain access to blood circulation. More importantly, the level of Lipid 654 was recovered
at significantly lower levels in the serum of patients with MS compared with both healthy individuals
and patients with Alzheimer’s disease. As a result, Lipid 654 may be an important blood biomarker
for multiple sclerosis.(Farrokhi, Nemati et al. 2013) Furthermore, Wang et al. showed that Lipid 654
can promote TLR2-dependent bone loss as is reported in experimental periodontitis following oral
infection with P. gingivalis.(Wang, Nemati et al. 2015) A diastereomeric mixture of (R,S)-Lipid
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662-D9 was used as quantitation references to simultaneously determine the absolute configuration
of the lipid moiety and quantify bacterial L-serine-Lipid 654. This approach is not only cost effective
as there is no need to obtain stereoisomerically pure ISs, but also allows for accurate quantitation of
both bacterial (R,S)-Lipid 654 stereoisomers in biological samples. cLC-SID-MRM, to our
knowledge, is utilized for the first time to quantify stereoisomers of lipopeptides.

2.2 cLC-SID-MRM MS analysis of Lipid 654 stereoisomers

2.2.1

Experimental

2.2.1.1 Research Facilities

All sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, Xudong Yao Lab, Chemistry Building). LC-TOF-MS
will be performed using 10ADvp system (Shimadzu) and quadrupole time-of-flight (QTOF) mass
spectrometer (QSTAR Elite, Sciex). LC-MRM-MS analysis was performed using the 10ADvp
system described above and 4000 QTRAP triple quadrupole mass spectrometer (Sciex). The mass
spectrometers are located in the MS facility of the Department of Chemistry (R403).

2.2.1.2 Material and Reagents
KCl, K2HPO4 and HPLC solvents were obtained from Thermo Fisher Scientific (Waltham,
MA). Tris base, CaCl2, glacial acetic acid, honey bee venom HBV-PLA2 (Apis mellifera, 6002400 units/mg protein) and diethylamine (DEA) were obtained from Sigma-Aldrich (St. Louis,
MO). Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized water.
Samples were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven or ultrasonic
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cleaner (Fisher Scientific, Waltham, MA), or lyophilizer (Labconco, Kansas City, MO). Incubation
of samples was performed on a Thermomixer R (Eppendorf, Hauppauge, NY).

2.2.1.3 ESI-MS/MS and MRM analysis
Tandem MS (MS/MS) spectra of synthetic Lipid 654, Lipid 430 and Lipid 662-D9 IS
(synthesis method to be reported elsewhere) were obtained by direct infusion of lipids at a flow
rate of 5 μL/min into a QTOF mass spectrometer, QSTAR Elite from Sciex (Framingham, MA),
in negative mode. Key instrument parameters were IS -4500 V, GS1 20, DP -80 V, CE -40 V, FP
-380 V, DP2 -10 V, and CAD 5. MRM transitions were selected based on known MS/MS spectra
of bacterial lipids, respectively. Lipid samples were directly infused into a triple quadrupole mass
spectrometer, 4000 QTrap from Sciex, for CE and DP optimization. MRM negative ion transitions
for Lipid 654 were m/z 653.5/306.2, 653.5/349.3 and 653.5/381.4, transitions for Lipid 430 were
m/z 430.2/400.3, 430.3/173.1 and 430.3/382.3. Transitions for IS were m/z 662.5/390.5,
662.5/358.4 and 662.5/315.3. Negative ion ESI-MRM MS analysis was carried out at IS −4500 V,
FP −350 V, EP −10 V using optimized values of CE and DP.
2.2.1.4 Method development of cLC
cLC method development was carried out as shown in Scheme 1. The method and column
selection were performed using a database comprising information of hundreds of chiral
compounds and methods that have been used for their separations (For more information one can
visit http://www.phenomenex.com). Three columns were tested for separation of stereoisomers of
synthetic (R,S)-Lipid 654; Lux Cellulose-4, Lux Amylose-2 and Lux Cellulose-1. For each
column, method development was started by trying NP solvent system (Scheme 1). If separation
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of Lipid 654 stereoisomers was not achieved, the polar phase and eventually RP solvent systems
were tested. For polar organic solvent system, diethylamine (DEA) was used as an additive for
mobile phase.

Lux 3 μm Cellulose-1,
Cellulose-4, and Amylose-2

Columns tested

HPLC Mode

Mobile Phase

NP

Hexane: IPA 8:2
Adjust %IPA

Polar Organic

Hexane: EtOH
9:1
Adjust % EtOH

MeOH: IPA
Add 1mM DEA

RP

A Water:ACN 6:4
B IPA:ACN 9:1
10mM AF, 0.1% FA

Scheme 1. cLC method development pipeline. Three columns were tested for separation of Lipid 654
stereoisomers. For each column, method development started with NP solvent system. If separation of Lipid
654 stereoisomers was not achieved, polar and RP modes were tested. IPA; 2-propanol, EtOH: ethanol,
MeOH: methanol, ACN: acetonitrile, DEA: diethylamine and FA: formic acid.

It is extremely important to condition the column before changing from NP to polar or from
polar to RP chromatography. When solvent switching was from NP to polar organic or from polar
organic to RP, columns were flushed by 10 time column volume of 2-propanol. When columns
were transferred from polar organic to NP, columns were flushed by 10 times column volume of
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methanol: ethanol 9:1, v/v. When not being used, columns were stored in hexane:2-propanol 9:1,
v/v.
2.2.1.5 cLC of Lipid 654
Synthetic L-serine-(R,S)-Lipid 654 as well as enriched L-serine-R-Lipid 654 and L-serineS-Lipid 654 diastereomers were dissolved in methanol:2-propanol (9:1, v/v) solvent separately. A
HPLC (10ADVP, Shimadzu, Columbia, MD) was used to isocratically separate stereoisomers of
L-serine-Lipid 654 using a chiral Lux Cellulose-4 50x 20 mmxmm, 5 μm (Phenomenex, Torrance,
CA) at 30°C. Mobile phase was composed of methanol:2-propanol (9:1, v/v) and 1 mM of DEA
and the solvent flow rate was 20 μL/min. The column was conditioned with methanol:2-propanol
(9:1, v/v) at a flow rate of 0.2 mL/min for at least 20 min before running separations and was kept
in hexane:2-propanol (9:10, v/v) after use.
To calculate t0 (retention time for un-retained eluents) while performing MRM
experiments, Qtrap 4000 capability of performing multiple experiments in one run was utilized.
Two experiments were defined as below: experiment 1:Q1MS between 100-1200 Da, and
experiment 2: MRM for Lipid 654 transitions. LC-MS parameters are similar to the cLC-MRM
MS experiment described above.
2.2.1.6 Characterization of (R,S)-Lipid 662-D9 IS
Solutions of 6.0 pmol/μL of synthetic (R,S)-Lipid 654 and 2.0 pmol/μL of diastereomeric,
isotopic ISs in methanol:2-propanol (9:1, v/v) were prepared for analysis using cLC-SID MRM
MS, with the same conditions described above.
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2.2.1.7 RP LC-SID-MRM MS analysis of bacteria Lipid 654
One hundred micrograms of total lipid extract of nine bacteria strains were dissolved in
acetonitrile:2-propanol:water (65:30:5, v/v/v) and were spiked with ISs to a final concentration of
600 fmol/μL. A RP column (XSELECT CSH C18 column 2.1 x 100 mm, 2.5 μm, Waters, Milford
MA) was used to separate the total lipid extracts under gradient conditions. Mobile-phase flow
rate was 160 μL/min. Solvent A was composed of 60% (v/v) water, 40% (v/v) acetonitrile, 0.1 %
(v/v) formic acid and 10 mM of ammonium formate. Solvent B was composed of 90% (v/v) 2propanol, 10% (v/v) acetonitrile, 0.1% (v/v) formic acid and 10 mM of ammonium formate. A
typical running gradient was 35% B at 0 min  75% B at 4 min  97% B at 11 min  35% B
at 12.1 min with a 2-minute column equilibration. MRM transitions for both L-serine-Lipid 654
and IS were monitored.
2.2.1.8 Quantitation of bacteria samples using cLC-SID-MRM MS
The same bacteria samples as described in the previous section were dissolved in
methanol:2-propanol (90:10, v/v). A chiral column (Lux Cellulose-4 50 x 20 mm, 3 μm) was used
to isocratically separate extracted lipids with a run time of 8 minutes. Mobile phase was composed
of methanol:2-propanol (90:10, v/v) and 1 mM DEA. Solvent flow rate was 50 μL/min and oven
temperature was 30°C. MRM transitions for L-serine-Lipid 654 and ISs were monitored using
similar parameters.
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2.3 Results and Discussion

2.3.1 Synthesis and MS/MS of stereoisomers of Lipid 654 and stable isotopic stereoisomers
as internal standards

All the syntheses mentioned in this section were carrid out by Christopher Dietz in the Dr.
Smith’s lab at the Chemistry Department of University of Connecticut.(Dietz, Hart et al. 2016)
Structure elucidation of bacterial Lipid 654 showed the presence of two chiral centers: one is on
the serine amino acid and the other one is on the lipid moiety of Lipid 654 lipopeptide.(Clark,
Cervantes et al. 2013) Since chiral GC-MS analysis of acid hydrolyzed Lipid 654 preparations
from bacteria revealed the presence of only L-serine, as reported previously,(Muhlradt, Kiess et
al. 1998, Clark, Cervantes et al. 2013) only L-serine was used for the synthesis of Lipid 654 and
Lipid 662-D9 IS. For the second chiral center on the fatty acid moiety, racemic 3-OH iso C17:0
was successfully used to prepare synthetic (R,S)-Lipid 654 and (R,S)-Lipid 662-D9 IS.(Dietz, Hart
et al. 2016) The only structural difference that (R,S)-Lipid 662-D9 has compared to (R,S)-Lipid
654 is that the deuterated ISs have one fatty acid with straight chain and nine deuterium atoms
(Figure 1c). Nevertheless, L-serine-Lipid 662-D9 IS shows the same MS/MS spectrum as Lserine-Lipid 654, allowing for accurate quantitation of L-serine-Lipid 654 stereoisomers (Figure
1c). Also, enantioenriched R- and S-Lipid 654 were synthesized utilizing a stereoselective
reduction as the key step,(Shioiri, Terao et al. 1998) using a ruthenium catalyst along with (R)BINAP and (S)-BINAP as chiral auxiliaries, respectively, in 98% ee.(Dietz, Hart et al. 2016)
Chemical structure of R- and S-Lipid 654 are shown in Figure 1c and 1d. MS/MS spectra of the
synthetic R- and S-Lipid 654 confirmed successful synthesis of the lipid molecules (Figure 1a and
1b). Both R- and S-Lipid 654 show the same MS/MS spectra. Therefore, there are no isoform-
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specific precursor-to-fragment transitions available for differential quantitation the R and S
isoforms.

Figure 1. Structure of synthetic R- and S-Lipid 654 and (R,S)-Lipid 662 D9-IS stereoisomers and their
MS/MS spectra. (a) MS/MS spectrum and structure of R-Lipid 654. Structure of the fragments that are
used for MRM are shown as well. (b) MS/MS spectrum and structure of S-Lipid 654. (c) MS/MS spectrum
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and structure of (R,S)-Lipid 662-D9-IS. IS also shows a complementary MS/MS pattern. Four fragments
with 9 Da mass shifts are observed which corresponds to the fragments that carry deuteriums within the
fatty acid.

Since Lipid 654 stereoisomers show identical MS/MS spectra, front-end separation is
required to quantify R and S isoforms by MS approaches. Ion mobility spectrometry (IMS) is an
emerging technology to separate lipid isomers in the gas phase prior to MS analysis.(Kyle, Zhang
et al. 2016, Jónasdóttir, Papan et al. 2015b, Damen, Isaac et al. 2014, Milic, Kipping et al. 2015,
Shvartsburg, Isaac et al. 2011) Lipid IMS-MS studies include classification of lipid molecules and
distinguishing double bond positions.(Damen, Isaac et al. 2014, Groessl, Graf et al. 2015, Paglia,
Kliman et al. 2015) Furthermore, coupling LC and IMS prior to MS analysis is advantageous due
to orthogonality of IMS to LC separation. Therefore, IMS increases the overall peak capacity in
LC separations.(Kyle, Zhang et al. 2016) LC-IMS MS has been recently exploited for separating
stereoisomers of lipids.(Kyle, Zhang et al. 2016, Jónasdóttir, Papan et al. 2015b)

2.3.2 cLC separation of (R,S)-Lipid 654 isoforms

Another possibility for separating stereoisomers of Lipid 654 is to use specific molecular
interactions afforded by the stationary phase of cLC. Column selection was based on matching
functional groups of Lipid 654 with functional group indices available on the Phenomenex
website. These indices are based on hundreds of chiral compounds that are screened. Using this
information, selection of candidate columns were narrowed down to three columns: Lux Cellulose1 with the stationary phase of cellulose tris(3,5 dimethylphenylcarbamate), Lux Amylose-2 with
the stationary phase of amylose tris(5-chloro-2-methylphenylcarbamate) and Lux Cellulose-4
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with the stationary phase of cellulose tris(4-chloro-3-methylphenylcarbamate) all from
Phenomenex, Torrance CA (Figure 2).

Figure 2. Phenylcarbamate derivatives of cellulose and amylose CSPs used for (R,S)-Lipid 654. (a)
Lux Cellulose-4, (b) Lux Amylose-2 and (c) Lux Cellulose-1. (Adopted from Phenomenex website)

Since the mechanism of the recognition is not fully understood, all three columns were
tested for (R,S)-Lipid 654 as described in experimental section. Lipid 654 stereoisomers were
successfully separated using a Lux Cellulose-4 column (50 x 20 mm, 5 μm) under isocratic
conditions. Mobile phase was composed of methanol:2-propanol (9:1,v/v) and 1mM DEA and the
mobile phase flow rate was 20 μL/min. The oven temperature was set at 30°C with (Figure 3c).
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Figure 3. cLC separation of Lipid 654 stereoisomers. cLC-MRM MS analysis of (a) synthetic
enantioenriched S-Lipid 654, (b) synthetic enantioenriched R-Lipid (c) synthetic (R,S)-Lipid 654
diastereomeric mixture.

Separation of stereoisomers using selected columns is based on differential interactions of
isomers with cellulose and amylose phenylcarbamate derivatives. Chiral recognition for these
CSPs significantly changes with type and position of substituents on the phenyl group.(Chen,
Yamamoto et al. 2007) Only the Lux Cellulose-4 column achieved successful separation of (R,S)Lipid 654 stereoisomers and the molecular mechanism behind this separation capacity still requires
further investigation. MRM MS was used to detect eluted R and S isoforms. Based the retention
times of pure R- and S-Lipid 654 isoforms, the first peak was assigned as R-Lipid 654 and the
second peak was assigned as S-Lipid 654 (Figure 3a, 3b and 3c).
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Figure 4. Simultaneous Q1MS and MRM MS experiments using QTrap 4000 upon cLC separation
of (R,S)-Lipid 654. (a) Q1MS experiment to calculate t0 shown by an arrow. (b) MRM experiment
monitoring Lipid 654 transitions. Only one transition is shown.

Utilizing simultaneous cLC Q1MS and MRM experiments in one run as described in
experimental section t0 was calculated, which is needed to calculate separation parameters in cLCMRM MS experiments (Figure 4). Separation parameters of retention time (tR), retention factor
(k), selectivity factor (α) and asymmetric factor of the analytes were thus determined and
summarized in Table 1. Analyses were carried out in triplicate.
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Peak (3 replicates)

tR (min)

A

w (min)

k

α

As

R-Lipid 654

12.8 (±0.1)

1.7e6 (± 0.1 e6)

1.9 (±0.1)

0.7 (±0.1)

1.3 (±0.1)

1.7 (±0.1)

S-Lipid 654

14.4 (±0.1)

1.6e6 (±0.1e6)

1.9 (±0.1)

0.9 (±0.1)

1.3 (±0.1)

1.6 (±0.1)

Table 1. cLC separation of (R,S)-Lipid 654. TR is retention, A is peak area, k is retention factor,
α is selectivity factor and As is the asymmetry factor for each peak.

Both R- and S-Lipid 654 have small amount of the other stereoisomer as the synthesis
method resulted primarily in enantioenriched R- and S-Lipid 654 stereoisomers (Figure 2b and
2c). Also, there is a minor peak that eluted from the cLC column after the S isoform. This peak
corresponds to the presence of a small amount of anteiso-C15:0 fatty acid when Lipid 654 or IS are
synthesized. Anteiso-C15:0 provides a third chiral center in the molecule and thus the retention time
of this stereoisomer is different from (R,S)-Lipid 654 stereoisomers (Figure 3c).

2.3.3 Characterization of (R,S)-Lipid 662-D9 IS for cLC-SID-MRM MS analysis of (R,S)Lipid 654

In order to assess the suitability of L-serine-(R,S)-Lipid 662-D9 as a diastereomeric
mixture of ISs to accurately quantify stereoisomers of L-serine-Lipid 654, LC-MS/MS
characteristics of synthetic L-serine-(R,S)-Lipid 654 and ISs were compared. Accurate
quantitation can be achieved provided that LC-MS/MS characteristics of isotopically labeled ISs,
including retention times and fragmentation patterns, are similar. As described previously the
MS/MS fragmentation pattern of (R,S)-Lipid 662-D9 is similar to that of Lipid 654 (Figure 1). A
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9 Da m/z shift was observed for the fragment ions that contain 3-hydroxy C17:0 heavy fatty acid
with nine deuterium atoms. To assess the chromatographic behavior of (R,S)-Lipid 654 and (R,S)Lipid 662-D9 IS, LC-MRM MS of synthetic (R,S)-Lipid 654 that was spiked with (R,S)-Lipid
662-D9 IS was carried out as described in the experimental section. Our cLC-MRM MS resulted
similar chromatographic separation, shown in extracted ion chromatogram (XIC), for (R,S)-Lipid
654 and (R,S)-Lipid 662-D9 (Figure 5 and Table 2). Separation power of cLC and quantitation
capabilities of MRM experiments allowed for quantifying both stereoisomers of synthetic Lipid
654 simultaneously.

Figure 5. cLC-MRM MS analysis of synthetic (R,S)-Lipid 654 and (R,S)-Lipid 662-D9.
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Percentage of R- and S-isoforms of the IS were calculated and were compared with
corresponding synthetic Lipid 654 (Table 2). Utilizing a diastereomeric mixture of ISs and cLC
separation of these stereoisomers using Lux Cellulose-4 column, enabled the development of a
novel method of cLC-SID-MRM MS method to identify the stereochemistry of bacterial Lipid 654
and quantify its stereoisomers simultaneously if both isoforms are present.

Sample

R-isoform tR

S-isoform tR

R-isoform %

S-isoform %

Lipid 662-D9 IS

5.8 (±0.1)

6.5 (±0.1)

29 (±1)

30 (±1)

Lipid 654

5.9 (±0.1)

6.6 (±0.1)

31 (±1)

29 (±1)

Table 2. Characterization of R-Lipid 662-D9 as IS for quantitation of (R,S)-Lipid 654. Retention time
(tR) and percentage of each isoform in total lipid calculated using XIC of each Lipid in cLC-MRM MS.

Accuracy and precision for quantitation of both R- and S-Lipid 654 using cLC-SID-MRM
MS were calculated and summarized in (Table 3). Solutions of synthetic (R,S)-Lipid 654 with the
concentration of 6.0 pmol/μL were spiked with (R,S)-Lipid 662-D9 with the concentration of 2.0
pmol/μL. Hence, the expected ratio for Lipid 654 to IS was 3. cLC-SID-MRM MS was utilized to
quantify R- and S-Lipid 654. Quantitation using R- or S-isoforms of Lipid 654 and Lipid 662-D9
resulted in very good accuracy and precision, similar to quantitation using the whole peak area of
(R,S)-Lipid 654 and (R,S)-Lipid 662-D9. As a result, cLC-SID-MRM MS can be utilized for
quantitation of stereoisomers of lipopeptides with a good accuracy and precision as long as a
racemic or diastereomeric mixture of isotopically labeled IS of lipopeptides is available.
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Sample

R-654/R-662

S-654/R-662

Lipid 654/Lipid 662

Calculated ratio

2.79

3.03

2.94

% Accuracy

92.9

100.9

97.9

% CV

1.4

1.7

1.0

Table 3. Precision and accuracy of cLC-SID-MRM MS for quantitation of R- and S-Lipid 654.

2.3.4 cLC-SID-MRM MS analysis of bacterial total lipid extracts

The developed cLC-SID-MRM MS method was used to analyze the total lipid extract of bacteria
from nine different strains. Three transitions for both Lipid 654 isomers and IS were monitored:
653.5/306.2, 653.5/349.3 and 653.5/381.4 m/z for Lipid 654 and 662.5/390.5, 662.5/358.4 and
662.5/315.3 for IS. All of bacterial strains showed a single peak in XIC of Lipid 654, which coeluted with the R isoform of IS, indicating the bacteria strains only produce R isoform of Lipid
654 (Figure 6a). As a result, R percentage of IS was used to quantify R-Lipid 654 in bacterial
samples using Equation 1.

CR654 =

XR IS =

Peak area for bacterial R Lipid 654
(Peak area for R IS )

Peak area for R IS
peak area for IS

× CIS × XR IS

Equation 1

Equation 2
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Figure 6. RP and cLC-SID-MRM MS quantitation of Lipid 654 in bacterial samples. XIC for Lipid
654 and IS using. Lower graphs show the XIC of IS and upper graph for Lipid 654 using (a) cLC-SIDMRM MS and (b) RP LC-SID-MRM MS.

CR 654 is the concentration of bacterial R-Lipid 654 and CIS is concentration of IS spiked in
bacterial samples. To further validate cLC-SID-MRM MS quantitation of bacterial R-Lipid 654,
these results were compared with those obtained using RP LC-SID-MRM MS (Table 3). (R,S)Lipid 662-D9 stereoisomers eluted from the C18 column as a single peak, co-eluting with Lipid
654, indicating no separation of Lipid 654 or IS stereoisomers (Figure 6b). Comparison between
the two methods was done by dividing the ratios of Lipid 654 and IS obtained from cLC-SIDMRM MS and RP LC-SID-MRM MS methods (Table 4). Chiral/RP ratios for Lipid 654 were
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calculated, giving an average ratio of 1.0 (Table 4) confirming that all of the analyzed bacteria
produce only R isoform of Lipid 654. Both methods show somewhat similar precision and
accuracy in quantitation of bacterial Lipid 654. However, coupling separation power of cLC and
using diastereomeric mixture of IS provides additional information that is not accessible by RP
LC-SID-MRM MS; i.e., simultaneous determination of stereochemistry and amount of Lipid 654.
Another advantage of using a diastereomeric mixture of ISs, as opposed to using pure
stereoisomers, is the synthesis of racemic or diastereomeric mixtures are easier and more cost
effective. This cost advantage further augments when expensive isotopes are used to produce ISs.

(Chiral)
Sample

R Lipid 654
R IS

Coefficient of

(RP)

Coefficient of

variation (CV)

Lipid 654/IS

variation (CV)

Chiral/RP ratio

× X R Lipid 654
T. denticola

0.19

3.43

0.19

7.33

1.0

P. endodontalis

110

11.2

120

10.1

0.96

FD 0450

35

3.12

37

4.26

0.94

FD 0580

0.25

13.1

0.23

7.48

1.1

P. gingivalis

100

10.3

89

12.5

1.2

P. intermedia

33

4.84

31

7.12

1.0

B. forsythia

12

4.47

11

4.14

1.1

P. distasonis

2.8

5.71

2.6

6.23

1.1

70

3.29

68

6.77

1.0

W83 P.
gingivalis

Table 4. RP and cLC-MRM MS quantitation of Lipid 654 in bacterial samples.
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2.3.5 Linearity of cLC-SID-MRM MS quantitation

L-serine-(R,S)-Lipid 662-D9 showed two groups of peaks that co-elute with the
corresponding peaks from synthetic L-serine-(R,S)-Lipid 654. To investigate the linearity of the
method of cLC-SID-MRM MS, calibration curves were generated for both L-serine-R- and Lserine-S-Lipid 654. Serially diluted L-serine-Lipid 662-D9 were added to vials containing a pooled
total lipid extract. Ratios of peak areas of L-serine-R- and L-serine-S-Lipid 662-D9 to the peak
area of endogenous bacterial Lipid-654 were plotted separately versus concentration of spiked ISs.
R2 values of 0.9992 and 0.9998 were obtained for L-serine-R and L-serine-S Lipid 662-D9,
respectively. Bacterial samples containing L-serine-(R,S)-Lipid 662-D9 in a range of 0.1 to 100
nmol/mL were quantified by cLC-SID-MRM MS. Limits of detection were calculated to be 10
pmol/mL of L-serine-Lipid 662-D9 for both L-serine-R- and L-serine-S-isoforms of Lipid 662-D9
(Figure 7 and 8).
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Figure 7. Calibration curve for R-Lipid 654 using serial dilution of (R,S)-Lipid 654-D9 spiked to a
pooled bacterial total lipid extract. Ratio of R-Lipid 654-D9 to bacterial Lipid 654 is plotted against
concentration of IS spiked in each sample.
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Figure 8. Calibration curve for S-Lipid 654 using serial dilution of (R,S)-Lipid 654-D9 spiked to a
pooled bacterial total lipid extract. Ratio of S-Lipid 654-D9 to bacterial Lipid 654 is plotted against
concentration of IS spiked in each sample.

2.4 Conclusions

Lipopeptides have recently emerged as promising vaccines, antibiotics and anticancer agents. Due
to the presence of multiple chiral centers in their structure, lipopeptides usually exert their
biological activity via stereoselective interactions with immune receptors such as TLRs. Therefore,
determination of the absolute configuration of the chiral building blocks of lipopeptides is of great
importance. So is the accurate quantitation of lipopeptide stereoisomers for assessing the safety
and efficacy of synthetic lipopeptide vaccines or antibiotics or to identify novel lipopeptide
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biomarkers for human disease. Combining the separation power of cLC and use of a diastereomeric
mixture of isotopic ISs with the clinically-proven quantitation potential of MRM MS, a novel and
robust method of cLC-SID-MRM MS is developed to simultaneously determine the
stereochemistry and quantify the amount of bacteria-derived L-serine-Lipid 654 in total lipid
extract of complex samples. This method is demonstrated for analysis of bacteria samples and also
applied to study a novel enzymatic conversion of L-serine-Lipid 654, a potential disease
biomarker. cLC-SID-MRM MS presents a sensitive and powerful platform for quantitative
investigation of stereoselective chemical or biological processes.
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Chapter 3

3

Mass spectrometry-based study of enzymatic hydrolysis of Lipid 654: relationship
between hydrolysis of Lipid 654 and human disease

3.1 Introduction
Phospholipases A2 (PLA2s) enzymes catalyze the hydrolysis of the sn-2 fatty acyl ester of
phosphoglyceride releasing a free fatty acid, predominantly arachidonic acid and a
lysophospholipid (Figure 1).(Burke, Dennis 2009a) PLA2s comprise a large family of proteins
found in various mammalian cells and tissues as well as in the venoms of snakes, scorpions and
bees.(Six, Dennis 2000) PLA2s are divided into 16 groups based on their source, catalytic activity,
amino acid sequence, chain length, and disulfide bond pattern.(Samel, Vija et al. 2013) The first
type of PLA2s discovered, were secreted or secretory PLA2s (sPLA2). All sPLA2s have low
molecular weight (13–19 kDa), histidine in the catalytic site, Ca2+-bound in the active site, and six
conserved disulfide bonds with one or two additional variable disulfide bonds.(Burke, Dennis
2009a) Mechanism of all sPLA2-catalyzed hydrolysis reactions includes abstraction of a proton
from a water molecule followed by a nucleophilic addition on the carbonyl of the sn-2 bond.
Histidine/aspartic acid dyad in the active site of sPLA2s activates the water molecule in a Ca2+dependent manner.(Scott, White et al. 1990) It has been shown, using biochemical analyses of
purified sPLA2 preparations, that individual sPLA2s exhibit substrate selectivity towards either
the phospholipid polar head groups or the sn-2 fatty acid constituent.(Murakami, Sato et al. 2015)
For example, sPLA2-IIA shows higher activity for phosphatidylethanolamine (PE) or
phosphatidylserine (PS) compared with phosphatidylcholine (PC). However, sPLA2-X has much
higher affinity for PC. It has also been suggested that the substrate selectivity is partly attributable
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to structural differences of sPLA2s.(Murakami, Sato et al. 2015) Furthermore, sPLA2s have very
important biological and physiological functions.(Murakami, Sato et al. 2015, Lambeau, Gelb
2008)

Figure 1. Phospholipase cleavage sites. Phospholipase A1 cleaves the sn-1 acyl chain, phospholipase A2
cleaves the sn-2 acyl chain and releases predominantly arachidonic acid, phospholipase C cleaves proximal
to the phosphate head group and releases diacylglycerol as well as a phosphate-containing head group and
phospholipase D cleaves distal to the phosphate releasing phosphatidic acid and an alcohol.

Biochemistry

and

physiology

of

mammalian

sPLA2s

have

been

studied

extensively.(Lambeau, Gelb 2008, Boyanovsky, Webb 2009, Murakami, Sato et al. 2015) Wellestablished functions of sPLA2 are their roles in digestion of dietary phospholipids and in innate
immunity against bacterial infections.(Richmond, Boileau et al. 2001, Buckland, Wilton 2000,
Movert, Wu et al. 2013, Weiss 2015) Furthermore, several studies indicated critical functions of
sPLA2s in arachidonic acid release and eicosanoid generation as well as in atherosclerosis.(Ghosh,
Tucker et al. 2006, Hurt-Camejo, Camejo et al. 2001, Bonnefont-Rousselot 2016, Kimak,
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Strycharz-Dudziak et al. 2015, Murakami, Sato et al. 2015) The role of sPLA2s in inflammation
leading to atherosclerosis and eicosanoid biosynthesis is one of the important areas of ongoing
PLA2 research.(Lambeau, Gelb 2008, Murakami, Sato et al. 2015)
The association between sPLA2 activity and atherosclerosis as well as between periodontal
conditions and vascular disease have been investigated separately in large-scale studies names
Coronary Event and Periodontal Disease (CORODONT) and Oral Infection and Vascular Disease
Epidemiology Study (INVEST).(Mallat, Benessiano et al. 2007, Desvarieux, Demmer et al. 2003,
Desvarieux, Demmer et al. 2005, Spahr, Klein et al. 2006) As a part of INVEST project, Boillot
et al. investigated the relationship of periodontal microbiota and PLA2s in order to study the link
between periodontal infections and cardiovascular disease such as atherosclerosis.(Boillot,
Demmer et al. 2015) They suggested that increased activity of sPLA2s might provide a
mechanistic explanatory link for the relationship between dysbiotic periodontal microbiota and
vascular diseases.(Boillot, Demmer et al. 2015)
Periodontal or gum diseases include a group of oral inflammatory infections that are
initiated by oral pathogens residing on the teeth or in the gingival sulcus surrounding the
teeth.(Costalonga, Herzberg 2014) Periodontal diseases can also lead to the destruction of
periodontal tissues by promoting loss of attachment of connective tissue and supporting bone for
teeth.(Wang, Nemati et al. 2015) The spectrum of periodontal diseases spans from reversible
chronic inflammation of gingiva to chronic inflammatory disease that results in destruction of
connective tissues and bone, which eventually can lead to the loss of teeth.(How, Song et al. 2016)
There is a significant difference between the subgingival periodontal microbiota observed in
gingival health versus chronic inflammatory periodontal disease.(Hajishengallis, Darveau et al.
2012, Colombo, Magalhães et al. 2016, Costalonga, Herzberg 2014) Hajishengallis et al. suggested
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that there is a “keystone-pathogen” that although is present in low abundance, can lead to
inflammatory disease by shifting a normally symbiotic microbiota into a dysbiotic
one.(Hajishengallis, Darveau et al. 2012) They indicated that Porphyromonas gingivalis (P.
gingivalis), which is considered a major periodontal pathogen, could represent as the keystonepathogen; P. gingivalis impairs innate immunity by evading Toll like receptor (TLR) recognition.
As a result, P. gingivalis changes the growth and development of the entire biofilm and triggers a
destructive change in the normally homeostatic host–microbiota interaction in the
periodontium.(Hajishengallis, Darveau et al. 2012, Darveau 2009)
Nichols and his collaborators previously reported that the total lipid extract of P. gingivalis
promotes activation of mouse dendritic cells and inhibits osteoblast-mediated bone deposition
through engagement of TLR2.(Wang, Jiang et al. 2010, Nichols, Housley et al. 2009) Accordingly,
Liquid chromatography-mass spectrometry (LC-MS) methods were developed to identify
biological active components of P. gingivalis responsible for the observed biological activities.
Following structure elucidation of an active component using MS/MS and NMR spectroscopy, it
was concluded that a serine dipeptide lipid, called Lipid 654, is a primary component of P.
gingivalis lipids responsible for activating TLR2.(Clark, Cervantes et al. 2013) It was suggested
that Lipid 654 engages TLR2 co-receptors, TLR6 and CD-14, in a manner similar to known TLR2
activator ligands such as diacylated lipopeptide Pam2Cys (Figure 2).
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Figure 2. Bacterial Lipid 654 effects on HEK cells stably transfected to express human TLR2. Cells
were treated with either PBS (Controls) or P. gingivalis-derived Lipid 654 (1 ug/ml) with or without the
indicated neutralizing antibodies. This experiment was completed together with Emily Anstadt at the Dr.
Robert Clark lab from Department of Immunology at UCONN Health Center.

LC-MS analysis of total lipid extract of P. gingivalis also indicated the presence of another
serine dipeptide lipid molecule called Lipid 430 based on its mass. Structure of Lipid 430 is similar
to Lipid 654, but lacks the ester-bound C15:0 fatty acid (Figure 3). Lipid 430 was also isolated and
biological activity of the isolates were investigated by Dr. Nichols lab.
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Figure 3. Structure of a) Lipid 654 and b) Lipid 430. Lipid 430 has structure similar to Lipid 654, but
lacks the ester-linked C15:0 fatty acid.

Bacterial Lipid 430 also significantly inhibited osteoblast gene expression and
differentiation, and mineral nodule formation.(Wang, Nemati et al. 2015) However, these effects
were only minimally contributed to engagement of TLR2. Osteoblasts are the primary cells
responsible for bone formation. More importantly, Lipid 430 stimulated tumor necrosis factor
alpha (TNF-α) and gene expression of receptor activator of nuclear factor kappa-B ligand
(RANKL) in wild type bone marrow cells, but not in TLR2 knockout cells. In searching for the
relationship between serine dipeptide lipids of P. gingivalis and human diseases such as chronic
periodontitis and vascular diseases, a LC-MS method was developed to quantify the amount of
these lipids in various biological matrices. Results showed that the level of Lipid 430 in bacteria
samples is very low relative to Lipid 654. However, the relative amount of Lipid 430 compared to
Lipid 654 is significantly higher in gingivalis tissue and carotid atheroma lipid extracts. Therefore,
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it was hypothesized that there is a metabolic conversion of Lipid 654 to Lipid 430 in the diseased
tissue. Commercially available esterase enzymes were screened for their capability for hydrolyzing
Lipid 654 to Lipid 430 under physiological pH and ionic strength. Of the esterase enzymes
evaluated, only PLA2 enzymes were observed to hydrolyze Lipid 654. The goal of the present
research is to exploit MS-based approaches to study PLA2-mediated hydrolysis of Lipid 654 to
Lipid 430 in order to better clarify a potentially very important relationship among PLA2 activity,
periodontal pathogens and human diseases including chronic periodontitis and atherosclerosis.
3.2 Quantitation of Lipid 654 and Lipid 430 in bacteria and human tissue samples using
normal phase (NP) LC-MRM MS
3.2.1 Experimental
3.2.1.1 Research Facilities
Sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, the Xudong Yao Lab, Chemistry Building) at
University of Connecticut and Department of Periodontology (room L1061, the Frank Nichols lab)
at University of Connecticut Health Center. LC-TOF-MS will be performed using a 10ADvp
Shimadzu HPLC (Columbia, MD) and quadrupole time-of-flight (QTOF) mass spectrometer
(QSTAR Elite, Sciex). LC-MRM-MS analysis was performed using a 10ADvp Shimadzu HPLC
and a QTRAP 4000 triple quadrupole mass spectrometer (Sciex, Framingham MA). The mass
spectrometers are located in the MS facility of the Department of Chemistry (R403). ELISA assay
was performed at the Department of Immunology (room ARB, the Robert Clark lab) at University
of Connecticut Heath Center.
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3.2.1.2 Material and Reagents
Acetyl chloride, Chloroform, and diisopropylethylamine (DIEA) were obtained from
Sigma (St. Louis, MO). Pentafluorobenzyl bromide, N,O-bis(trimethylsilyl)triflouroacetamide
(BSTFA), trypsin (0.25%) in EDTA (1X), and HPLC solvents were obtained from Thermo Fisher
Scientific (Waltham, MA). Lipoteichoic acid was obtained from InvivoGen (San Diego, CA).
Direct-Q3 water system (Millipore, Billerica, MA) was used to purify deionized water. Samples
were dried using SpeedVac (Savant, Farmingdale, NY), vacuum oven (Fisher Scientific, Waltham,
MA), or lyophilizer (Labconco, Kansas City, MO). Incubation of samples was performed on a
Hula Mixer (Invitrogen, Waltham, MA) or a Thermomixer R (Eppendorf, Hauppauge, NY).
3.2.1.3 Lipid extraction and LC fractionation (by Dr. Nichols lab)
Lipid extraction and LC fractionation of extracted lipids were done by the Dr. Nichols’ lab.
Lipids were extracted from lyophilized bacterial pellets and human samples using the method of
Bligh and Dyer as modified by Garbus.(GARBUS, DELUCA et al. 1963) Bacterial samples were
dissolved in chloroform:methanol:water (1.33:2.67,1, v/v/v, 4 ml). The mixture was vortexed at
15 min intervals for 2 h and the mixture was supplemented with 0.75 ml of chloroform and 0.75
ml of (2M KCl + 0.5M K2HPO4). The mixture was then vortexed and centrifuged (2000 g) at 20°C
for 4 h. The lower organic phase was removed and dried under nitrogen. Carotid endarterectomy
samples were recovered at the time of surgical excision, a portion of each atheroma was removed
for pathological evaluation and the remainder of the sample was frozen until processing. Control
carotid arteries from young adults were recovered at necropsy as fresh frozen samples as processed
at the National Disease Research Interchange. Frozen samples were thawed and minced into small
pieces. Lipid extraction from tissue samples was performed using the same procedure as bacterial
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samples. The dried artery samples were dissolved in chloroform and the total lipid content was
determined. A known amount of synthetic Lipid 662-D9 internal standard (IS) ([M-H] m/z 662.5)
was added to each lipid sample in order to quantify the level of Lipid 654 in the artery samples.
The dried extract was reconstituted in 24 mL of HPLC grade solvent (hexane:2propanol:water, 6:8:0.75, v/v/v) and vortexed for 30 seconds. The samples were centrifuged at
2500 g for 10 minutes and the supernatant removed for HPLC analysis. Semipreparative HPLC
fractionation was accomplished using a Shimadzu HPLC system equipped with dual pumps (LC10ADvp), automated controller (SCL-10Avp) and in line UV detector (SPD-10Avp). Lipids were
fractionated using a NP silica column (Ascentis®Si, 25 cm x 10 mm, 5 μm, Supelco, St. Louis
MO) under isocratic conditions with a solvent flow rate of 1.8 mL/min and eluents were collected
in 1 min fractions. The eluates were monitored at 205 nm. For pooled lipid extracts of carotid
atheroma samples, replicate fractionations were pooled and dried under nitrogen. The dried
samples were reconstituted in the HPLC solvent for mass spectrometric analysis as described
below. Fractions containing Lipid 654 were pooled and dried before additional HPLC
fractionation. HPLC fractions containing Lipid 654 or Lipid 430 were further purified for Lipid
by injecting the fractions over the same HPLC column at 1.8 mL/min, but using HPLC solvent
supplemented with 0.1% acetic acid. The purity of Lipid 654 and Lipid 430 fractions was verified
by direct infusion of the HPLC fractions into Qstar Elite as described previously.
3.2.1.4 NP LC-MRM MS analysis of Lipid 654 and Lipid 430 in bacteria and tissue samples
A 10ADvp Shimadzu HPLC was used to isocratically separate total lipid extract of bacteria
and tissue samples using an Ascentis column, 2.1 x 50 mm, 3 μm (Supelco, St. Louis MO) packed
with NP silica gel. Shimadzu HPLC was interfaced with a QTrap. Mobile phase was hexane:2-
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propanol:water (6:8:0.75, v/v/v) and flow rate for HPLC separation was 0.12 mL/min. Negative
ion ESI-MRM experiments were carried out at -4,500 V, with a declustering potential (DP) of -90
V, focusing potential (FP) of -350 V, and entrance potential (EP) of -10 V. The ion source
temperature was maintained at 300°C. Multiple reaction monitoring (MRM) negative ion
transitions for Lipid 654 were m/z 653.5/131.1, 653.5/306.2, 653.5/349.3 and 653.5/381.4 and for
transitions for Lipid 430 were m/z 430.2/140.9, 430.3/173.1 and 430.3/382.3. CE values were
optimized for each transition. Lipid 430/Lipid 654 ratios were calculated using only the m/z
430.3/382.3 and 653.5/381.4 transitions. The synthetic IS was monitored using m/z 662.5/390.5,
662.5/358.4 and 392.5/315.3. Lipid 654 amount per mg of total lipid extract was determined using
the ratio of endogenous Lipid 654 to deuterated IS from integrated transitions peaks using Analyst
1.6 software.
3.2.1.5 Statistical analysis
Normally distributed data sets are expressed as the mean ± standard deviation, for which
statistical paired Student’s t-test was applied. For data sets that did not satisfy a normal distribution,
the results were depicted as Box Whisker plots and Kruskal-Wallis test or Mann-Whitney U-test
were applied. A p value of <0.05 was considered to be significant.
3.2.2 Results and discussion
LC-MS approaches were used to evaluate the recovery of Lipid 654 and Lipid 430 in lipid
extracts of human carotid atheroma samples. Lipid extracts from carotid atheroma samples (n=12)
were pooled and fractionated first by NP HPLC as previously described. The fractions containing
Lipid 654 were pooled and re-fractionated over the same column but using HPLC solvent
supplemented with 0.1% acetic acid. Lipid 654 was recovered primarily in one fraction (acidic
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HPLC fraction 13) of carotid atheroma fractionated lipids and Figure 4A shows the MS spectrum
indicating the characteristic 3 negative ions (m/z 654.2, 640.3 and 626.1) for the Lipid 654 class.
Lipids of P. gingivalis were fractionated using the same method and the maximum abundance of
the Lipid 654 lipid class was observed in HPLC fraction 14 (Figure 4B). MS/MS analysis of the
most abundant negative ion species of the Lipid 654 class (m/z 653.5) recovered in fraction 13 of
pooled endarterectomy lipids is shown in Figure 4C. Also, MS/MS spectrum of the dominant Lipid
654 species recovered in HPLC fraction 14 of P. gingivalis lipids is shown in Figure 4D. Lipid
654 isolated from P. gingivalis and atheroma samples showed identical MS/MS fragmentation
patterns indicating that lipid extracts from carotid atheroma samples contained bacterial Lipid 654.
This finding is of great significance in that it could reveal a potential link between periodontal
pathogens, especially P. gingivalis, and atherosclerosis.
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Figure 4. Lipid 654 recovered in pooled carotid atheroma lipid extracts. (A) ESI-MS spectrum of a
Lipid 654-enriched fraction from a pooled carotid atheroma samples. Lipid extracts from 12 carotid
atheroma samples were pooled and fractionated first by using a neutral HPLC solvent fractionation
followed by pooling fractions containing Lipid 654 and re-fractionating with acidic HPLC solvent. (B) ESIMS spectrum of a Lipid 654-enriched fraction from P. gingivalis. (C) MS/MS spectrum of Lipid 654
extracted from atheroma samples. (D) MS/MS spectrum of Lipid 654 extracted from P. gingivalis.

Total lipid extracts from fourteen oral Bacteroidetes species and four intestinal
Bacteroidetes species were analyzed for Lipid 430 and Lipid 654 as described in the Methods
section. LC-MRM MS showed that bacteria produce significantly less Lipid 430 than Lipid 654.
The Lipid 430/Lipid 654 ratios ranged from 0.001 to 0.006 (Figure 5A) and these ratios were
averaged for all bacteria analyzed. Furthermore, NP LC-MRM MS was utilized to quantify the
amount of Lipid 654 and Lipid 430 in lipid extracts of individual carotid endarterectomy samples
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(n=12) and carotid artery samples of healthy individuals between the age of 16 and 36 (control
artery samples obtained from the National Disease Research Interchange, Philadelphia, PA, n=6
samples) (see Figure 5B). All carotid artery lipid extracts contained detectable levels of Lipid 654
and Lipid 430. Figure 5C shows the average level of Lipid 654 relative to a fixed amount of Lipid
662-D9 IS normalized by weight of total lipid analyzed for carotid endarterectomy and control
artery samples. The average level of Lipid 654 per milligram of total lipid extract was four-fold
less in carotid atheroma lipid samples compared with the control artery samples. Reduced levels
of Lipid 654 in total lipid extract of carotid endarterectomy samples could result from dilution of
Lipid 654 due to the accumulation of cholesterol and other atherogenic lipids or metabolic deesterification of Lipid 654 in diseased artery walls. The median Lipid 430/Lipid 654 ratio observed
in carotid atheroma samples was almost five-fold higher than that observed in the control artery
samples, supporting the possibility of more hydrolysis of Lipid 654 to Lipid 430 in diseased
arteries. Therefore, if cholesterol accumulation causes a net decrease in the relative amount of
Lipid 654 in diseased artery walls, it is not reflected in a similar dilution of Lipid 430 in the same
samples.
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Figure 5. Recovery of Lipid 430 and Lipid 654 in common Bacteroidetes species, carotid artery
samples and human serum samples analyzed by LC-MRM MS. (A) Level of Lipid 654 and Lipid 430
in total lipids extract of 14 bacteria strains (oral and gastrointestinal Bacteroidetes) were analyzed using NP
LC-ESI-MRM MS. Lipid 430/Lipid 654 ratios were calculated by dividing the peak area of the most
abundant transitions for Lipid 430 and Lipid 654 (430.3/382.3 for Lipid 430 and 653.5/381.4 for Lipid 654)
are shown for each bacterial total lipid extract. (B) Lipid 430/Lipid 654 ratios are shown for carotid
atheroma samples, carotid normal artery samples, total lipid extract of different strains of bacteria and serum
from healthy adult subjects. Lipid samples were analyzed using ESI-MRM MS. The asterisk indicates a
significant difference from all other sample categories by one way ANOVA on ranks test. (C)
Quantification of Lipid 654 levels in carotid artery total lipid extracts using NP LC-SID-MRM MS. Lipid
654 per milligram of total lipid was determined using the ratio of endogenous Lipid 654 to deuterated IS.
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Results are depicted as the mean ± standard deviation and the significance level was determined by paired
Student’s t-test.

It was interesting to compare relative amounts of Lipid 430 and Lipid 654 in bacteria
samples and tissue samples were compared. The median ratios of Lipid 430 to Lipid 654 for carotid
atheroma and control carotid artery samples were compared to bacterial lipid extracts (Figure 5).
The carotid atheroma samples showed a median Lipid 430/Lipid 654 that is about 180 times greater
than that observed in Bacteroidetes species, and 16 times greater than that observed in carotid
artery samples from healthy young subjects. The differences among these sample categories are
statistically significant. Because the median Lipid 430/Lipid 654 ratio in carotid atheroma samples
is significantly higher than that observed in cultured Bacteroidetes species, these results do not
support the notion that live Bacteroidetes are prevalent in carotid atheroma.
Although all human carotid artery samples tested were contaminated with detectable levels
of Lipid 654 and Lipid 430, the median ratio of Lipid 430/Lipid 654 recovered in Bacteroidetes
species is inconsistent with the distribution of the serine dipeptide lipids in carotid artery samples.
Therefore, direct invasion of the artery walls by live bacteria is not likely to account for the serine
lipid recovery in carotid artery samples. In addition, the levels of these lipids in serum samples
suggests that Lipid 654 rather than Lipid 430 is preferentially transported in blood or blood cells
and the elevated recovery of Lipid 430 in diseased carotid arteries probably resulted from the
conversion of Lipid 654 to 430 in cells located on or in the diseased artery wall.
The present study demonstrated that serine dipeptide lipids derived from organisms of the
oral and intestinal human microbiome are also present in human carotid artery samples. Though
we have not established that all Bacteroidetes species are capable of synthesizing Lipid 654 and
Lipid 430, a survey of common oral and intestinal species showed that only Bacteroidetes species
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produce substantial amounts of these serine dipeptide lipids (Figure 5A). The HPLC fractionation
of pooled carotid atheroma lipids and LC-MS analysis confirmed that Lipid 654 is present in
substantial amounts in lipid extracts of carotid atheroma samples. However, the absolute amount
of Lipid 654 as a percentage of the total lipid present was 4-folds lower in the total lipid extracts
of carotid atheroma samples compared with the control carotid artery samples (Figure 5C). This
observation could be related to the substantial accumulation of cholesterol, triglycerides, and other
atherogenic lipids in the carotid atheroma samples, which essentially dilute the amount of Lipid
654 in the total lipid extract, or it could represent the accumulation of Lipid 654 before mammalian
atherogenic lipids begin to accumulate in substantial amounts. If atherogenic lipids and Lipid 654
accumulate together in carotid atheroma and the Lipid 654 is not metabolically broken down, the
Lipid 654 levels would remain essentially unchanged as a percentage of the total lipid present.
However, because the median Lipid 430/Lipid 654 ratio is substantially different from that in
bacteria and serum samples, one explanation could be de-esterification of Lipid 654 to Lipid 430,
which could explain the lower levels of Lipid 654 in atheroma versus healthy carotid artery.
3.3 MS-based study of enzymatic hydrolysis of Lipid 654 to Lipid 430
3.3.1 Experimental
3.3.1.1 Research Facilities
Sample preparations were performed in a Biosafety Level 2 laboratory within the
Department of Chemistry (R409 and R411, the Xudong Yao Lab, Chemistry Building) at
University of Connecticut and Department of Periodontology (room L1061, the Frank Nichols lab)
at University of Connecticut Health Center. LC-TOF-MS was performed using a 10ADvp
Shimadzu HPLC and a QSTAR Elite. LC-MRM-MS analysis was performed using a 10ADvp
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Shimadzu HPLC and a QTRAP 4000. The mass spectrometers are in the MS facility of the
Department of Chemistry (R403).
3.3.1.2 Material and Reagents
Tris-buffered saline (TBS) and trifluoroacetic acid (TFA) were purchased from Fisher
Scientific (Waltham, MA). 1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0 PC) was
purchased from Avanti (Alabaster, AL). HPLC grade chloroform, Lyophilized cobra venom factor
(CVF) (Ophiophagus Hannah, King Cobra), porcine pancreatic PLA2 (PP PLA2, >600 units/mg
protein), honey bee venom PLA2 (HBV-PLA2) (Apis mellifera, 600-2400 units/mg protein),
phospholipase A1 (PLA1) (Thermomyces lanuginosus), phospholipase C (PLC) (Clostridium
perfringens, 10-50 units/mg protein), phospholipase C (PLD) (Arachis hypogaea, 300-700
units/mg protein), lipoprotein lipase (LL) (Pseudomonas sp., >50,000 units/mg protein),
Pentafluorobenzyl bromide and N,O-bis(trimethylsilyl)triflouroacetamide (BSTFA) were
obtained from Sigma (St. Louis, MO). Direct-Q3 water system (Millipore, Billerica, MA) was
used to purify deionized water. Samples were dried using SpeedVac (Savant, Farmingdale, NY),
or lyophilizer (Labconco, Kansas City, MO). Incubation of samples was performed on a Hula
Mixer (Invitrogen, Waltham, MA) or a Thermomixer R (Eppendorf, Hauppauge, NY). Sonication
was performed using ultrasonic cleaner (Fisher Scientific, Waltham, MA) or ..(Dr. Nichols lab).
3.3.1.3 Enzymatic hydrolysis of P. gingivalis-derived Lipid 654. Screening of various esterase
enzymes
Purified samples from P. gingivalis were dissolved in chloroform and aliquoted at 10 μg
into 5 ml conical reaction vials and dried under nitrogen. One milliliter of TBS buffer (10 mM, pH
7.4) with 10 mM CaCl2 was added to each vial. The samples were sonicated for 20 seconds using
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an ultrasonic sonicator and approximately 100U of HBV-PLA2 and PP-PLA2 and approximately
400U of lyophilized LL, CVF, PLA1, PLC and PLD were added to each vial. To quench the
reaction at each time point, samples were acidified with glacial acetic acid (25 μL). Then, 1mL of
chloroform was added for lipid extraction and the mixture was vortexed vigorously. Upon
separation of the two organic and aqueous phases, the lower phase (chloroform) was transferred
to a new tube. The upper layer was extracted with 1mL of chloroform for two more times. All
three extractions were pooled and dried under nitrogen. For LC-MS analysis, samples were
dissolved in hexane:2-propanol:water, (6:8:0.75, v/v/v).
3.3.1.4 18O-labeling investigation of the enzymatic hydrolysis reaction and MS analysis of
hydrolysis products
One thousand and eight hundred microliters of a buffer solution (10 mM TBS and 2.5 mM
CaCl2, pH=7.4) was lyophilized. A total volume of 1800 μL of 18O-water was then added to the
lyophilized buffer to form our 18O-Buffer. Fifty microliters of 18O-Buffer was added to each aliquot
(10 μg) of lipid substrate. Substrates include Lipid 654, iso-C15:0 fatty acid, and 14:0 PC. Solutions
were incubated at room temperature for 10 minutes and then sonicated for 5 minutes in an
ultrasonic cleaner. Another 50 μL of 18O-Buffer was added to each aliquot of enzyme (50 μg of
HBV-PLA2 and PP-PLA2). Solutions were incubated at room temperature for 10 minutes and
mixed for another 10 minutes at room temperature and 800 rpm. Enzyme and substrate solutions
were mixed and briefly vortexed to let the enzymatic hydrolysis reaction start. For control samples
instead of enzyme solutions, another 50 μL of
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O-Buffer was added to the substrate solutions.

Five aliquots of Lipid 654 samples were used for a time-course experiment and were mixed with
5 aliquots of PP-PLA2. Incubations were stopped at 3. 5, 6 h, 16 h, 48 h and 75 h. Another set of
experiments included Lipid 654 with HBV-PLA2, iso-C15:0 fatty acid with both PP-PLA2 and
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HBV-PLA2, as well as control samples (control experiments are the lipid samples including Lipid
654, iso-C15:0 fatty acid or anteiso-C15:0 fatty acid without PLA2 enzyme) were stopped after 75 h
of incubation. At the conclusion of hydrolysis reactions, 5 μL of glacial acetic acid was added to
the reaction mixtures to quench the reaction and 500 μL of chloroform was added to extract the
lipids after the reaction. The mixture were vortexed vigorously. Upon separation of the two organic
and aqueous phases, lower phase (chloroform) was transferred to a new tube. To the upper layer,
another 500 μL of chloroform was added for the second extraction. The latter step was repeated
one more time. All three extractions were pooled and dried under nitrogen. Samples were analyzed
for fatty acid release using both GC-MS and NP LC-ESI MS.
3.3.1.5 Fatty acid analysis (Performed by the Dr. Nichols lab)
Fatty acids that are released after PLA2 catalyzed hydrolysis of Lipid 654 in 18O-Buffer
were converted to pentafluorobenzyl ester derivatives by reacting fatty acid extracts in a mixture
of acetonitrile, DIEA, pentafluorobenzyl bromide (36:10:4, v/v/v, 50 μl) for 20 min at
50°C.(Nichols 1994) Derivatized fatty acid samples were analyzed using a 5975C gas
chromatography-MS (GC-MS) instrument from Agilent Technologies (Santa Clara, CA) equipped
with an Agilent HP-5M nonpolar column with a helium flow rate of 1 mL/min for both positive
and negative ionization conditions. The column was heated from 100 to 290°C. The injection block
and transfer line were maintained at 280° and 290°C, respectively. Methyl ester-MTPA derivatives
were run in the negative chemical ionization modes. Fatty acid quantification was accomplished
by integration of selected ion chromatograms of each fatty acid ion (including iso- and anteisoC15:0 fatty acids and their corresponding 18O- and 18O2-labeled ones).
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For LC-ESI MS analysis of fatty acids produced after hydrolysis reaction in
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O-Buffer,

samples were dissolved in hexane:2-propanol:water (6:8:0.75, v/v/v). A Shimadzu LC (10 ADVP) was used to isocratically separate lipid samples on an Ascentis column (2.1 x 50 mm, 3 μm,
Supelco, St. Louis MO) with a NP silica gel . A 10ADvp Shimadzu HPLC was interfaced with a
QTRAP 4000. Mobile phase was hexane:2-propanol:water (6:8:0.75, v/v/v) and flow rate of HPLC
solvent was 0.12 mL/min. Negative ion ESI-Q1MS experiments were carried out at -4,500 V, with
a declustering potential (DP) of -90 V, focusing potential (FP) of -350 V, and entrance potential
(EP) of -10 V. The ion source temperature was maintained at 300°C. Extracted ion chromatograms
(XIC) of each fatty acid and their corresponding 18O-labeled species were monitored.
3.3.1.6 Synthesis of Lipid 430 stereoisomers
Lipid 430 as mentioned previously has two chiral centers. GC-MS analysis of bacterial
Lipid 430 showed that bacteria produce only L-serine.(Clark, Cervantes et al. 2013) As a result,
only L-serine but (R,S)-3-OH C17:0 fatty acids were used to synthetize a diastereomeric mixtures
of L-serine-(3R,3S)-Lipid 430, abbreviated as (R,S)-Lipid 430. (R,S)-Lipid 430 were synthesized
by Christopher Dietz in the Michael Smith lab at the Chemistry Department of University of
Connecticut.(Dietz, Hart et al. 2016)
3.3.1.7 Chiral LC separation of synthetic (R,S)-Lipid 430 and Lipid 430 produced after
hydrolysis of bacteria Lipid 654
Synthetic diastereomeric mixtures of (R,S)-Lipid 430 and Lipid 430 that is produced after
hydrolysis of P. gingivalis-derived Lipid 654 were analyzed using chiral LC-MS. a Chiralpak®OD
chiral column (250 x 4.6 mm, 10 μm, Daicel Corporation, Tokyo Japan) under isocratic conditions
was utilized to separate stereoisomers of Lipid 430. Mobile phase was hexane, 2-propanol (9:1,
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v/v) and 0.1% TFA at a flow rate of 0.6 ml/min. A UV-visible detector was used to monitor the
eluents at the wavelength of 205 nm.
3.3.1.8 ESI-MS/MS analysis of synthetic (R,S)-Lipid 430 and bacterial-derived Lipid 430
Tandem MS (MS/MS) spectra of synthetic (R,S)-Lipid 430, P. gingivalis Lipid 430 and
Lipid 430 from hydrolysis of Lipid 654 were obtained by direct infusion of lipids at a flow rate of
5 μL/min into a QSTAR Elite, in negative ion mode. Key instrument parameters were IS -4500 V,
GS1 20, DP -80 V, CE -30 V, FP -380 V, DP2 -10 V, and CAD 5.
3.3.1.9 Chiral LC-MRM MS analysis of PLA2 hydrolysis of (R,S)-Lipid 654
A diastereomeric mixture of synthetic (R,S)-Lipid 654 was dissolved in chloroform,
transferred into glass vials in 10 μg aliquots and dried under nitrogen. To the vials were added 100
μL of TBS (10 mM, pH 7.4) and 10 mM CaCl2. Resulting solutions were incubated for 10 minutes
without shaking at room temperature (RT) and then sonicated for 5 minutes in an ultrasonic
cleaner. Fifty microliters of the same buffer was added to vials containing 50 μg aliquots of
lyophilized HBV-PLA2 enzyme. Resulting solutions were incubated at RT for 10 minutes without
shaking and another 10 minutes on thermomixer at 1200 rpm. Then, enzyme solutions were
transferred to the vials containing Lipid 654 solutions except for the control samples. To quench
the hydrolysis reaction, reaction mixtures were acidified with 5 μL of glacial acetic acid and
extracted with chloroform (500 μL each for three times). The extracts were pooled and dried under
nitrogen and then dissolved in 100 μL of methanol: 2-propanol (9:1,v/v) for cLC-SID-MRM MS.
Three transitions (m/z 430.2/400.3, 430.3/173.1 and 430.3/382.3), in addition to the transitions for
Lipid 654 (m/z 653.5/131.1, 653.5/306.2, 653.5/349.3 and 653.5/381.4) were monitored to
measure the amount of Lipid 430 produced from hydrolysis of Lipid 654. A Shimadzu LC (10
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AD-VP) was used to isocratically separate the re-constitutes reaction products on a chiral column
(Lux Cellulose-4 50 x 20 mm, 5 μm, Phenomenex, Torrance CA). Mobile phase was composed of
methanol:2-propanol: diethylamine (DEA) (90:10:0.1). Solvent flow rate was 20 μL/min and oven
temperature was set at 30°C. A QTRAP 4000 was used to monitor MRM transitions for (R,S)Lipid 654 and Lipid 430.
3.3.2 Results and discussion
3.3.2.1 Identification of esterase enzymes catalyzing hydrolysis of Lipid 654
Of all the esterases tested, only HBV-PLA2 (a group III PLA2)(Burke, Dennis 2009a) and
PP-PLA2 (secretory PLA2 and group IB PLA2)(Murakami, Taketomi et al. 2011) enzyme
preparations hydrolyzed Lipid 654 to the Lipid 430 (Scheme 1). Other enzymes including PLA1,
PLC, PLD, LL and CVF showed minimal hydrolysis similar to the control sample without enzyme
(Figure 6). Also, PLA2 enzymes didn’t hydrolyze Lipid 654 in solution without Ca2+ ions.

100

Lipid 430/Lipid 654

10
8
6
4
2

0

Enzyme

Figure 6. Hydrolysis of Lipid 654 by various esterase enzyme preparations. Ratios of peak area for
Lipid 430 to peak area for Lipid 654 are shown. Most intense transitions (430.3/382.3 for Lipid 430 and
653.5/381.4 for Lipid 654) were used to calculate the peak area for each lipid.

The samples shown in Figure 6 were treated in neutral 10 mM TBS buffer (pH 7.4), but
PLA2 hydrolysis of the Lipid 654 was repeated in phosphate buffered saline (PBS) buffer and
physiological pH and produced the same results. Also, neither of PLA2 preparations contained
Lipid 654 or Lipid 430. PLA2 enzymes hydrolyze the ester bond formed on the second hydroxyl
of glycerol-based phospholipids. PLA2 levels are characteristically elevated at sites of chronic
inflammatory responses and result in the release of polyunsaturated fatty acids, predominantly
arachidonic acid. Arachidonic acid release is prerequisite for elevated prostaglandin synthesis. To
the best of our knowledge, there are no reports describing PLA2 hydrolysis of lipids other than
glycerol-based phospholipids. Lipid 654 is not a glycerol-based phospholipid but evidence
provided here suggests that both HBV-PLA2 and PP-PLA2 enzymes can de-esterify P. gingivalis
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Lipid 654 to Lipid 430 through a calcium dependent mechanism. Other esterases evaluated in this
investigation showed essentially no capacity to catalyze the hydrolysis of bacterial Lipid 654.
Therefore, the enzymatic de-esterification of bacterial Lipid 654 appears to be limited either to
specific enzymes of the PLA2 class. Porcine pancreatic PLA2 is a group IB enzyme and is
structurally distinct from honey bee venom PLA2 which is a group III enzyme.
3.3.2.2 18O-labeling to investigate the enzymatic hydrolysis reaction and MS analysis of
hydrolysis products
As indicated previously, preparations of HBV-PLA2 and PP-PLA2 catalyze the hydrolysis
reaction of Lipid 654 to Lipid 430 and C15:0 fatty acid (Scheme 1). In order to confirm the
enzymatic hydrolysis, determine the breakage bond and obtain more mechanistic information, 18Olebaling and MS were exploited. LC-ESI MS analysis of hydrolysis products strongly suggested
that upon enzymatic hydrolysis of Lipid 654 with PP-PLA2 and HBV-PLA2 in 18O-Buffer, one or
two 18O atoms reside on the cleaved C15:0 fatty acid. However, minimal incorporation of 18O atoms
was observed on cleaved Lipid 430 (Table 1). Fatty acid analysis using GC-MS further validated
LC-MS results in that C15:0 fatty acid incorporate one or two 18O atoms (Table 1 and 2).

Consequently, these results suggested that HBV-PLA2 and PP-PLA2 facilitate cleavage of
the bond between acyl group and oxygen atom on ester-bound C15:0 fatty acid (Scheme 1). In order
to more mechanistically investigate the enzymatic hydrolysis of Lipid 654, we designed a timecourse experiment, in which products of PP-PLA2 hydrolysis of Lipid 654 in

18

O-Buffer were

monitored after 3.5, 6, 16, 48 and 75 h as described in experimental section.

102

Scheme 1. Enzymatic hydrolysis of Lipid 654 with PLA2 enzymes in 18O-Buffer. One or two 18O atoms
are added to C15:0 fatty acid upon hydrolysis of Lipid 654. Cleavage site is shown by a red dashed line.

In addition to the time-course experiment, incorporation of 18O by standard synthetic isoC15:0 was also monitored (with and without the presence of PLA2 in
C15:0 was our control experiment for incorporation of

18

18

O-Buffer); synthetic iso-

O by C15:0 fatty acid released upon

hydrolysis of Lipid 654. Furthermore, 14:0 PC (Figure 7), a standard substrate for PLA2 enzymes,
was also treated with HBV-PLA2 and PP-PLA2 in 18O-Buffer for 75 h under similar conditions.
Later experiment was designed to compare the PLA2-facilitated hydrolysis of Lipid 654 with a
known PLA2 substrate. LC-ESI MS and GC-MS were utilized to analyze all the

18

O-labeling

experiments and the results of these analyses are shown in Table 1 and 2, respectively.
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Figure 7. Structure of C14:0 PC, a standard substrate for PLA2s. PLA2s catalyze the hydrolysis of the
sn-2 fatty acyl ester of C14:0 PC releasing a free C14:0 fatty acid.
18

O-lebaling clearly showed that PP-PLA2 and HBV-PLA2 catalyze a direct attack of water

on the carbonyl of C15:0 acyl group of Lipid 654, presumably by general base catalysis by histidine
as shown previously for their standard substrates.(Lombardo, Fanni et al. 1986, Burke, Dennis
2009b, Yu, Dennis 1991) Also, our control experiments including incubation of synthetic iso-C15:0
fatty acid in 18O-Buffer with and without PLA2s for 75 h showed rather a minimal incorporation
of 18O at similar conditions (Table 1 and 2). Lombardo et al. also reported no incorporation of 18O
when a standard C16:0 fatty acid ([1-13C] palmitic acid) was reacted with PLA2 in 18O-water buffer
(Tris-HCl pH 7.9) for 24 h at 40 oC.(Lombardo, Fanni et al. 1986) Although the presence of PLA2
increased the incorporation of 18O from approximately 4 to 8% (based on LC-MS data) or 2 to 7%
(based on GC-MS data), these incorporations cannot explain the significant amount of second 18O
incorporated by cleaved C15:0 fatty acid upon hydrolysis of Lipid 654 (Table 1 and 2). These results
suggested that

18

O-labeling of free fatty acids through the exchange of H218O is not possible in

these conditions. Also, PLA2 cannot efficiently catalyze the exchange of H218O of free fatty acids
under similar conditions. PLA2 hydrolysis of C14:0 PC (a known substrate for PLA2s) also showed
cleavage of sn-2 position as expected and incorporation of one 18O to the released C14:0 fatty acid.
This latter result is also in agreement with the work of Lombardo et al. in that released fatty acid
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incorporated one 18O and doesn’t exchange the second oxygen.(Lombardo, Fanni et al. 1986) In
striking contrast, C15:0 fatty acid that is released upon hydrolysis of Lipid 654, incorporates the
second

18

O atom and the percentage of

18

O2-C15:0 fatty acid increases while the percentage of 18O-

C15:0 fatty acid decreases between 3.5 and 75 h time points (Table 1 and 2). On the other hand, the
percentages of released Lipid 430 and 18O-Lipid 430 didn’t change significantly after 3.5 h (Figure
8).

Figure 8. LC-ESI MS analysis of products of PP-PLA2 hydrolysis of Lipid 654 (a time-course
experiment). a) Percentage of 16O-C15:0 fatty acid, 18O-C15:0 fatty acid and 18O2-C15:0 fatty acid calculated
after 3.5, 6, 16, 48 and 75 h. b) Percentage of 16O-Lipid 430 and 18O-Lipid 430 calculated after the time
points mentioned above.

These results suggest that PLA2-Lipid 654 complex is different from PLA2-PC complex
in that cleaved C15:0 fatty acid is retained longer or released from active site slower in such a way
that incorporation of the second

18

O is possible; this is most likely due to the presence of high
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energy transition state after breakdown of tetrahedral intermediate (such as fatty acid release or
conformational change of the enzyme’s active site).(Lombardo, Fanni et al. 1986, Burke, Dennis
2009b) Nevertheless, further investigation is required to further test these hypotheses.

LC-ESI MS
Source, Lipid, Enzyme, Incubation time\Monitored ion

16

O-lipid

18

O-Lipid

18

18

O2-Lipid

O-Lipid
%

18

O2-Lipid
%

Standard synthetic, iso-C15:0, Ctrl, 75 hr

7.7E+08

3.1E+07

0

3.9

0

Standard synthetic, iso-C15:0, PP-PLA2, 75 hr

8.6E+08

7.2E+07

4.2E+06

7.8

0.4

Cleaved, iso-C15:0, PP-PLA2, 3.5 hr

3.1E+07

2.2E+08

1.0E+08

62.8

28.5

Cleaved, iso-C15:0, PP-PLA2, 6 hr

2.5E+07

2.5E+08

1.4E+08

59.6

34.4

Cleaved, iso-C15:0, PP-PLA2, 16 hr

3.1E+07

2.2E+08

1.6E+08

53.2

39.5

Cleaved, iso-C15:0, PP-PLA2, 48 hr

3.2E+07

1.8E+08

1.9E+08

44.9

47.1

Cleaved, iso-C15:0, PP-PLA2, 75 hr

2.5E+07

1.4E+08

2.0E+08

38.8

54.2

Cleaved, iso-C15:0, HBV-PLA2, 75 hr

6.4E+07

2.4E+08

2.1E+08

46.7

40.7

Cleaved, C14:0, PP-PLA2, 75 hr

0

3.4E+08

4.6E+08

42.4

57.7

Cleaved, C14:0, HBV-PLA2, 75 hr

0

3.7E+08

4.8E+08

43.8

56.2

Cleaved, Lipid 430, PP-PLA2, 3.5 hr

6.3E+08

6.8E+07

0

9.8

0

Cleaved, Lipid 430, PP-PLA2, 6 hr

7.1E+08

8.0E+07

0

10.1

0

Cleaved, Lipid 430, PP-PLA2, 16 hr

9.3E+08

1.2E+08

0

11.6

0

Cleaved, Lipid 430, PP-PLA2, 48 hr

9.6E+08

1.2E+08

0

11.4

0

Cleaved, Lipid 430, PP-PLA2, 75 hr

6.5E+08

8.4E+07

0

11.5

0

Table 1. NP LC-ESI MS analysis of products of PLA2 hydrolysis of Lipid 654 and C14:0 PC in 18OBuffer. Products of hydrolysis reactions were extracted and analyzed by NP LC-ESI MS. Peak area of XIC
for each hydrolytic lipid product (endogenous and 18O-labeled) are shown, except the first two row that
show the incubation of standard iso-C15:0 fatty acid without and with PP-PLA2, respectively. Shown are
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also the percentage of 18O- and 18O2-labeled Lipid products. Note: Peak area of XICs, for which integration
was not possible is reported as zero.

GC-MS
18

Endogenous
lipid

Standard synthetic, iso-C15:0, Ctrl, 75 hr

1.9E+07

4.1E+05

0

2.1

0

Standard synthetic, iso-C15:0, PP-PLA2, 75 hr

2.2E+07

1.7E+06

0

7.0

0

Cleaved, iso-C15:0, PP-PLA2, 3.5 hr

1.3E+06

8.3E+06

3.4E+06

63.9

26.3

Cleaved, iso-C15:0, PP-PLA2, 6 hr

6.9E+05

9.5E+06

5.1E+06

62.3

33.2

Cleaved, iso-C15:0, PP-PLA2, 16 hr

1.4E+06

8.7E+06

5.8E+06

54.6

36.5

Cleaved, iso-C15:0, PP-PLA2, 48 hr

8.3E+05

6.6E+06

6.3E+06

48.2

45.7

Cleaved, iso-C15:0, PP-PLA2, 75 hr

1.1E+06

6.5E+06

6.8E+06

45.0

47.4

Cleaved, iso-C15:0, HBV-PLA2, 75 hr

1.0E+06

6.8E+06

5.3E+06

51.6

40.5

Cleaved, C14:0, PP-PLA2, 75 hr

1.3E+06

1.2E+07

1.4E+07

44.3

50.8

Cleaved, C14:0, HBV-PLA2, 75 hr

1.8E+06

1.5E+07

1.7E+07

44.1

50.7

18

O-Lipid

18

O2-Lipid

O-Lipid
%

18

Source, Lipid, Enzyme, Incubation time\Monitored ion

O2-Lipid
%

Table 2. GC-MS fatty acid analysis of products of PLA2 hydrolysis of Lipid 654 in 18O-Buffer.
Products of hydrolysis reactions were extracted and were derivatized for GC-MS analysis. Peak
area of XIC for each hydrolytic lipid product (endogenous and 18O-labeled) are shown, except the first two
row that show the incubation of standard iso-C15:0 fatty acid without and with PP-PLA2, respectively.
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Shown are also the percentage of 18O- and 18O2-labeled Lipid products. Note: Peak area of XICs, for which
integration was not possible is reported as zero.

3.3.2.3 Synthesis, separation and LC-MS of Lipid 430 stereoisomers
As discussed in the experimental section, the stereochemistry of serine amino acid of Lipid
654 was already determined to be L-serine by chiral GC-MS analysis, which was done by the Dr.
Nichols lab at University of Connecticut Health Center as described previously.(Clark, Cervantes
et al. 2013) To determine the absolute structure of Lipid 430 that is produced upon hydrolysis of
Lipid 654, L-serine-(3R,3S)-Lipid 430 stereoisomers, abbreviated as (R,S)-Lipid 430, were
synthesized by Christopher Dietz in the Dr. Michael Smith’s laboratory at the Chemistry
Department of University of Connecticut.(Dietz, Hart et al. 2016) An off-line chiral LC-MS
method was utilized to separate and validate the synthesis of (R,S)-Lipid 430 as described in the
experimental section. Both stereoisomers of synthetic Lipid 430 were successfully separated using
a Chiralpak®OD column under isocratic conditions. Chiral HPLC separation of synthetic (R,S)Lipid 430 eluted as two peaks at 25 and 30 minutes, respectively, giving a selectivity α to be
1.3(Figure 9b). Also, Lipid 430, produced after hydrolysis of Lipid 654 from P. gingivalis, was
isolated using acidic fractionation of the hydrolysis products with NP HPLC as described in the
experimental section. The Lipid 430 fraction was fractionated on the same chiral column that was
used to separate synthetic (R,S)-Lipid 430. However, Lipid 430 produced from enzymatic
hydrolysis of P. gingivalis Lipid 654 yielded only one peak with the same retention time as the
first peak observed in chiral separation of synthetic (R,S)-Lipid 430 (Figure 9a), suggesting
structure of bacterial Lipid 430 is similar to one of the stereoisomers of synthetic (R,S)-Lipid 430.
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Figure 9. Chiral LC separation of Lipid 430 from hydrolysis of bacteria Lipid 654 and synthetic
diastereomeric mixture of (R,S)-Lipid 430. a) Chiral LC isolated Lipid 430 from PLA2 hydrolysis of P.
gingivalis-derived Lipid 654. b) Chiral LC separation of diastereomeric mixture of (R,S)-Lipid 430. Both
peaks have the same MS and MS/MS spectra. LC-MS analysis of the fractions was used to assign the peaks.
(Done in the Dr. Nichols lab)

In order to further validate the synthesis of (R,S)-Lipid 430 and compare these samples
with Lipid 430 produced after PLA2 hydrolysis of Lipid 654, high resolution MS/MS analysis of
these samples were performed as described in the experimental section. Synthetic (R,S)-Lipid 430
and Lipid 430 produced by hydrolyzing P. gingivalis Lipid 654 showed similar MS/MS spectra
indicating the successful synthesis of (R,S)-Lipid 430 (Figure 10).
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Figure 10. ESI-MS/MS analysis of Lipid 430 preparations. MS/MS spectra of Lipid 430 at CE= -30 V
obtained by direct infusion of lipid samples. (a) Lipid 430 isolated after hydrolysis of Lipid 654 with PLA2.
(b) First peak in chiral separation of synthetic (R,S)-Lipid 430. (c) Second peak in chiral separation of
synthetic (R,S)-Lipid 430.

Chiral LC separation and MS/MS analysis of Lipid 430 from PLA2 hydrolysis of bacterial
Lipid 654 and synthetic (R,S)-Lipid 430 indicated that bacterial Lipid 654 molecules produce only
one of the Lipid 430 stereoisomers. These results lead to the postulations: 1) bacteria produce only
one of the possible L-serine-Lipid 654 stereoisomers, and 2) PLA2 catalyzes the hydrolysis of only
one Lipid 654 stereoisomers. Both stereoisomers of Lipid 654 were synthesized in order to
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investigate whether the stereoselectivity of PLA2 enzymes or the presence of only one isoform for
bacterial Lipid 654 is responsible for production of only one isoform for Lipid 430.
3.3.2.4 Stereoselctivity of PLA2 enzymes: chiral LC-MRM MS analysis of PLA2 hydrolysis
of (R,S)-Lipid 654
As described in chapter 2, a diastereomeric mixture of Lipid 654 stereoisomers, (R,S)Lipid 654 as well as enantioenriched R- and S-Lipid 654 were synthesized by Christopher Dietz
in the Dr. Michael Smith lab at the Chemistry Department of the University of Connecticut.(Dietz,
Hart et al. 2016) Using synthetic standards of Lipid 654, an online chiral LC-SID-MRM MS
method, coined as cLC-SID-MRM MS, was developed. cLC-SID-MRM MS analysis of bacterial
samples showed that all the bacteria produce only R-Lipid 654 confirming that hypothesis 1 is
correct. Nevertheless, to test the hypothesis 2, cLC-MRM MS was utilized to study
stereoselectivity of PLA2 enzymes in catalyzing the hydrolysis of Lipid 654 stereoisomers. The
PLA2 enzyme preparation was used to hydrolyze triplicate aliquots of synthetic (R,S)-Lipid 654
as described in the experimental section. For control experiments, triplicate aliquots of synthetic
(R,S)-Lipid 654 were incubated in hydrolysis buffer without PLA2 enzyme. Strikingly, cLC-MRM
MS clearly showed that PLA2 only hydrolyzes R-Lipid 654, the isoform of Lipid 654 that is
produced by bacteria (Figure 11). Control (R,S)-Lipid 654 with no hydrolysis showed two distinct
peaks (Figure 11c). The first peak was assigned as R-Lipid 654 and second peak as S-Lipid 654
based the retention time observed for enantioenriched R- and S-Lipid 654 (Figure 11a-b).
Furthermore, (R,S)-Lipid 654 aliquots without showed similar results as control samples with
incubation and no added enzyme. Stereoselectivity of PLA2 towards R-Lipid 654 is clear in Figure
11d. The peak for R-Lipid 654 was lost after PLA2 hydrolysis (Figure 11d) while S-Lipid 654
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showed essentially no change in ion abundance measured as integrated peak area. The Lipid 430
product of PLA2 hydrolysis was detected by monitoring three transitions (Figure 11d).

Figure 11. cLC-MRM MS analysis of PLA2 hydrolysis of (R,S)-Lipid 654. XICs of Lipid 654 and Lipid
430 transitions (m/z 430.2/400.3, 430.3/173.1 and 430.3/382.3 653.5/306.2, 653.5/349.3 and 653.5/381.4)
for (a) synthetic enantioenriched R-Lipid 654, (b) synthetic enantioenriched S-Lipid 654, (c) (R,S)-Lipid
654 before hydrolysis and (d) products of (R,S)-Lipid 654 hydrolysis with PLA2
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cLC-MRM MS established not only that PLA2 enzymes catalyze hydrolysis of Lipid 654,
but also that PLA2 enzymatic activity is stereoselective towards R-Lipid 654, which turns out to
be the predominant isoform of Lipid 654 produced by bacteria. Quantitative information regarding
selectivity of PLA2 in Lipid 654 hydrolysis is summarized in Table 3.

Sample\Peak area

R-Lipid 654

S-Lipid 654

Lipid 430

(R,S)-Lipid 654, control

1.7e6(± 9.4e4)
51%

1.6e6(±1.1e5)
49%

1.4e4(±2.6e3)

(R,S)-Lipid 654, PLA2 treated

3.9e4(±1.5e3)
3%

1.2e6(±1.0e5)
97%

4.1e5(±6.2e4)

Table 3. Peak area of R-Lipid 654, S-Lipid 654 and Lipid 430 before and after enzymatic hydrolysis.

3.4 Conclusions
Using LC-MS approaches, it was shown that commercially available preparations of PLA2
enzymes (PP-PLA2 and HBV-PLA2) catalyze hydrolysis of Lipid 654 to Lipid 430, which is a
novel activity for PLA2 enzymes. Also, LC-SID-MRM MS quantitation of Lipid 654 and Lipid
430 in bacteria and tissue samples, showed ratio of Lipid 430/Lipid 654 is increased in diseased
tissue samples. It was indicated that PLA2 hydrolysis of Lipid 654 to Lipid 430 can account for
lower level of Lipid 430 in diseased (atheroma) samples and may present a potential link between
PLA2 activity and atherosclerosis. The Combination of 18O-labeling and MS enabled us to further
characterize the hydrolysis reaction of Lipid with PLA2 enzymes. One or two 18O atoms reside on
the C15:0 fatty acid upon hydrolysis of Lipid 654. Time-course experiment revealed that the
incorporation of the second 18O could be due to the slow release of cleaved fatty acid from active
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site. cLC-MRM MS also showed preparations of PLA2 enzymes are stereoselective towards
hydrolysis of Lipid 654; PLA2 preparations selectively hydrolyze R-Lipid 654 isoform.
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Chapter 4

4 Conclusions and perspectives
Changes in the bacterial populations in specific locations in the body, particularly the
gastrointestinal tract and the oral cavity, are reported to be associated with localized diseases such
as periodontal disease as well as systemic diseases such as autoimmune diseases. Furthermore,
relationships between periodontal microbiota and vascular disease are also reported. Hence, a
considerable work has centered on characterization of products of human microbiome and their
roles in triggering innate immune responses that may promote chronic inflammatory disease. Tolllike receptors (TLRs) are innate immune receptors. These receptors have evolved to recognize
conserved products unique to microbial metabolism. Of note, a significant structure-activity
relationship controlling TLR2 binding and resulting activation of immune responses.
As discussed in chapter 1, the present work is split into two distinct sections. First part of
the present work has focused on developing mass spectrometry (MS)-based technologies to study
a subclass of complex lipids called lipopeptides that engage TLR2 and to investigate their
relationship with human disease. Notably, recognition of lipopeptides with TLR2 and subsequent
immune responses can be stereoselective. Separation power of chiral liquid chromatography (cLC)
and diastereomeric mixture of isotopically labeled ISs were utilized to develop a novel method of
cLC stable isotope dilution multiple reaction monitoring MS (cLC-SID-MRM MS) to
simultaneously determine structure and amount of stereoisomers of bacteria-derived lipopeptides.
Elucidation of complete structure of lipopeptides requires determination of absolute configuration
of all chiral building blocks; chiral amino acids and 3-hydroxyalkanoic acid. This process can be
very time-consuming. Also, enantiopure ISs are required to accurately quantify stereoisomers of
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lipopeptides. cLC-SID-MRM MS leverages the need for enantiopure ISs for quantitation of each
stereoisomers, which are not always available or costly to make. The present work utilized a
diastereomeric mixture of (R,S)-Lipid 654 as model compounds and showed that cLC-SID-MRM
MS can be used to simultaneously determine the configuration of 3-hydroxy C17:0 moiety of
bacterial Lipid 654 and quantify bacterial Lipid 654 in total lipid extract of nine bacteria strains.
In the second part of the presented study, LC-MRM MS approaches were implemented to
quantify Lipid 654 and their related lipopeptides in healthy and disease tissue samples and compare
these results to those of bacteria samples. It was shown that there is a significant amount of Lipid
654 in these tissue samples and more importantly, the level of Lipid 430, one of hydrolytic products
of Lipid 654, is elevated in diseased tissue samples. Therefore, we hypothesized that there is a
relationship between hydrolysis of these lipopeptides and human disease such as atherosclerosis.
LC-SID-MRM MS showed that hydrolysis of Lipid 654 to Lipid 430 is the most plausible
explanation for the observed lower level of Lipid 654 in atheroma samples. The association
between sPLA2 activity and atherosclerosis, and between periodontal conditions and vascular
disease have been investigated separately in other large-scale studies. Furthermore, it is suggested
that increased activity of PLA2s might provide a mechanistic explanatory link for the relationship
between dysbiotic periodontal microbiota and vascular diseases. Herein, presented work showed
another possible link between increased activity of PLA2 enzymes, periodontal pathogens and
atherosclerosis. It was shown, for the first, that preparations of PLA2 enzymes catalyze the
hydrolysis reaction of a non-glycerol phospholipid. PLA2s hydrolyze C15:0 ester-bound fatty acid
of Lipid 654. The combination of

18

O-lebaling and MS was successfully utilized to further

investigate PLA2 hydrolysis of Lipid 654. It was indicated that the cleavage site PLA2 hydrolysis
of Lipid 654 is similar to that of standard substrates of PLA2; the bond between oxygen and
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carbonyl group. However, contrary to PLA2 hydrolysis of PC (standard substrate for PLA2),
combination of 18O-lebaling and a time-course experiment strongly suggested that there is a slow
release of cleaved fatty acid upon PLA2 hydrolysis of Lipid 654, which lead to incorporation of
two 18O by cleaved C15:0. Finally, cLC-MRM MS was utilized to investigate stereoselectivity of
lipopeptide hydrolysis. It was shown that the described PLA2 enzymes predominantly hydrolyze
R-isoform of Lipid 654.
Overall, this work utilized various LC and MS methods to study bacteria-derived
lipopeptides and proposed a potential link between PLA2 hydrolysis of these lipopeptides and
human disease such as atherosclerosis. The ultimate goal of the present work was to use
bioanalytical technologies to answer compelling questions in biology and in particular in regards
to human disease. However, the research presented in this thesis has raised more questions that it
has answered. Of note, further mechanistic investigation of PLA2 hydrolysis of Lipid 654,
preferably using recombinant human PLA2, is required to validate the results obtained in this
presented research. Also, a chemical description of the action of PLA2 in regards to hydrolysis of
Lipid 654 can be inferred with high confidence if one uses a high resolution x-ray crystal structure
of PLA2 in a complex with Lipid 654 or its analogues. As for quantitation, collecting more
clinically-relevant samples to be analyzed in order to validate the presented results is of great
interest. Finally, more biological assays need to be designed to further explore the role of described
lipopeptides and their hydrolytic products. New diagnostic biomarkers of human health that
include members of the human microbiota and chemical messengers they form, and
Pharmaceutical applications based on novel enzymatic activities that are associated with the
human microbiota are ultimate goals of the present work.
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